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SELECTIVE FUNCTIONALIZATION OF PYRIDINES AND DIAZINES VIA 
NUCLEOPHILIC ADDITION TO HETEROCYCLIC PHOSPHONIUM SALTS 
 
 Nitrogen heterocycles, specifically pyridines and pyrimidines, are common motifs found 
in pharmaceuticals, agrochemicals and materials. Site-selective functionalization of these azines 
are highly sought after for medicinal chemistry purposes. It has previously been found in our lab 
that heterocyclic phosphonium salts can potentially serve as a useful functional handle to 
selectively functionalize these valuable scaffolds. This work describes the utility of heterocyclic 
phosphonium salts as electrophiles to selectively form C-O, C-S, C-N and C-Se bonds in a 
diverse range of pyridines and diazines. 
 First, the addition of thiolate nucleophiles to heterocyclic phosphonium salts to 
selectively form heteroaryl thioethers is described. This coupling reaction proceeds through 
deprotonation of the alkyl thiol followed by addition of the heterocyclic phosphonium salt under 
mild conditions. The reaction scope was tested for a variety of alkyl thiol nucleophiles as well as 
different pyridine phosphonium salts. The extent of the method’s utility was demonstrated 
through late-stage functionalization of some complex pharmaceuticals. Additionally, initial 
results on the reactivity of sulfinate nucleophiles with heterocyclic phosphonium salts is 
communicated. 
 Second, aromatic heteronucleophiles were explored for reactivity with heterocyclic 
phosphonium salts. Aromatic heteronucleophiles can be classified as either exocyclic or 
endocyclic. Exocyclic aromatic heteronucleophiles, such as phenols, thiophenols and anilines, 
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were able to be selectively coupled to azines and pharmaceuticals. Endocyclic aromatic 
heteronucleophiles, such as pyrroles, pyrazoles and imidazoles, also proved to be compatible. All 
these nucleophiles were able to be coupled to complex drug-like fragments as well as other 
bioactive molecules via the phosphonium ion. The method also enabled a convergent coupling 
reaction between two elaborate coupling partners to form a novel tyrosine kinase inhibitor that 
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CHAPTER 1: BACKGROUND ON SELECTIVE FUNCTIONALIZATION OF AZINES 
AND DIAZINES VIA HETEROCYCLIC PHOSPHONIUM SALTS 
1.1 Selective Functionalization of Pyridines and Diazines 
 Nitrogen-containing heteroaromatics are among the most prevalent structural motifs 
found in FDA approved pharmaceuticals.1 Pyridine is the second most common nitrogen 
heterocycle appearing in small-molecule drugs as they are present in 10% of all marketed 
therapeutics in the US.1a,e These 6-membered heterocycles have also shown useful applications 
in metal catalysis as ligands2 as well as in functional materials3 and agrochemicals (Figure 1.1).4 
This widespread popularity warrants a desire for new direct methods to functionalize these 
valuable azines.  
 
Fig. 1.1: Examples of various applications of pyridine motifs 
 Furthermore, it is a combined effort from the ring itself along with the substituents that 
protrude from its scaffold that allow for pyridine’s extensive use. For this reason, the 
development of new reactions that can regioselectively functionalize pyridine and other diazines 
are in high demand. The majority of pyridine functionalization reactions are either 2- or 3-
postion selective processes. There are much fewer methods available to selectively transform the 
4-position of the scaffold, leaving a large amount of chemical space that has yet to be explored 
by medicinal chemists.5 SOCl2-mediated reactions enable pyridine dimerizations6 and synergistic 
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Al/Ni catalysis enables C-C bond formations7. Additionally, a 4-selective perfluoroalkylation 
reaction has been demonstrated using a bulky borane Lewis acid activation strategy.8 All of these 
methods are examples of strategies where the targeted functional group is installed in a single 
step. While this approach is efficient in getting the desired functionality quickly, each type of 
desired bond construction requires its own chemical method to be developed. A more versatile 
approach to pyridine functionalization is to selectively install a functional handle that aids in 
various subsequent bond constructions (Figure 1.2). A functional handle approach is particularly 
appealing for drug discovery programs that seek access to a wide variety of pyridine analogues.  
 
Fig. 1.2: Pyridine functionalization via a versatile functional handle vs. specific bond 
constructions 
 
1.2 Heterocyclic Phosphonium Salts 
 Our laboratory has been developing a research program around heterocyclic 
phosphonium salts to serve as a generic functional handle for 4-selective functionalization of 
pyridines and diazines.9 The C-PPh3+ group is formed by subjecting the azaarene to sequential 
addition of Tf2O, PPh3 and an organic base at low temperatures (Figure 1.3).10 
 
Fig. 1.3: Heterocyclic phosphonium salt formation protocol 
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Nucleophilic addition of PPh3 on the activated triflyl pyridium salt (I) is has shown 
considerable selectivity at the 4-position (Figure 1.4). Computational analysis is ongoing, in 
collaboration with the Paton group, to probe at this observed selectivity. Currently, we believe 
that there is a lower activation energy barrier (ΔG‡) as well as a lower overall reaction energy 
(ΔGreact) for para attack over ortho. In addition, we also believe that attack at the 2-position is 
reversible but irreversible at the 4-position. Nucleophilic addition of PPh3 is followed up by 
base-mediated elimination of II allows for re-aromatization of the azine to form the heterocyclic 
phosphonium salt 1a. The process is broadly applicable for pyridines, diazines and quinolines 
that contain a wide range of steric and electronic properties including the late stage applications 
on complex drug molecules.9,11 
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CHAPTER 2: THIOLATE ADDITION TO HETEROCYCLIC PHOSPHONIUM SALTS 
2.1 Introduction 
 The electronic and steric properties of pyridines and diazines can be adjusted by adding 
heteroatom substituents to their scaffold. Specifically, C-S bond constructions on these electron 
deficient rings to form heteroaryl thioethers are of great interest to medicinal chemists.1 
Moreover, these thioether moieties are commonly found in biologically active molecules (Figure 
2.1).1,2a-c Another advantage of the thioether moiety is that it can serve as a precursor to higher 
oxidation state sulfoxide and sulfone derivatives, which are also commonly found in 
pharmaceuticals.2d  
 
Figure 2.1: Examples of heteroaryl thioethers in biologically active compounds 
 Existing methods to construct heteroaryl thioethers typically rely on metal-catalyzed 
cross-couplings or SNAr reactions, both of which require a halogenated precursor.3 Due to the 
need for this functional antecedent, thioether formation on heterocycles is limited by the lack of 
selective halogenation methods. This, in turn, leads to the inaccessibility of potentially valuable 
compounds for medicinal chemists. 
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 As previously mentioned in chapter 1, members of the McNally group had shown that 
heterocyclic phosphonium salts could be used as a more general approach for etherification of 
pyridines and diazines.4 They were also able to show a preliminary example of C-S bond 
formation using this method. With this in mind, it made sense to begin working on a more 
detailed account of this simple protocol to test its feasibility.5 Figure 2.2. demonstrates the 
general transformation for this two-step procedure. The 4-position C-H bond is transformed into 
the bench stable phosphonium salt via the protocol described in chapter 1. The phosphonium ion 
can then serve as an electrophilic handle to facilitate the C-S bond formation with the thiolate 
nucleophile. The coupling procedure involves deprotonating the thiol at 0 ºC with sodium 
hydride in THF followed by addition of the phosphonium salt and stirring at room temperature.  
 
Figure 2.2.: Two step protocol for construction of heteroaryl thioethers 
 
 The mechanism for which this transformation proceeds remains unclear, however, there 
are two distinct pathways that can be imagined (Figure 2.3). Pathway A demonstrates a ligand-
coupling mechanism where the thiolate adds to the phosphonium to from a P(V) phosphorane 
intermediate. This phosphorane would then undergo a ligand coupling process to give off the 
triphenyl phosphine and form the desired thioether.6 This proposed mechanistic pathway 
resembles C-O couplings that are postulated to proceed through alkoxyphosphorane 
intermediates.7 We assume that the thiolates would be analogous to this process. SNAr is another 
potential route that cannot be ignored (Figure 2.2.3 (B)).8 In this case, triphenyl phosphine would 
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be the leaving group which is a by-product that is always observed with the desired C-S bond 
formation. Mechanistic studies continue to be a topic of focus in the McNally lab.  
 





 Before analyzing reactivity with variable substitution patterns, we wanted to try to 
optimize the reaction conditions to improve them and attempt to increase the yield. The initially 
reported C-S coupling reaction4 was ran at in THF (0.25 M) at room temperature for 12 hours, 
using 1.5 equivalents of the alcohol and sodium hydride. Table 2.2.1 depicts the results of the 
optimization screen that was conducted on triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethane sulfonate (1a) and benzyl thiol (figure 2.4). All reactions were ran at 0.25 mmol 
scale using 1,3,5 trimethoxy benzene as an internal standard. The crude mixtures were 





Figure 2.4: The test reaction used for optimization. All reactions were ran at 0.25 mmol scale 
 
Table 2.1: Optimization results for the reaction depicted in scheme 2.2.1 
Entry Concentration (M) Rxn. Time Equivs. of thiol % Yield 1H NMR 
1 0.25 12 1.5 83% 
2 0.125 12 1.5 81% 
3 0.08 12 1.5 59% 
4 0.25 3 1.5 84% 
5 0.25 3 1.25 81% 
6 0.25 3 1.1 81% 
7 0.25 3 1 76% 
 
Entries 1-3 of table 2.1 showed how changing the concentration of the reaction effected 
the yield. We didn’t go any more concentrated than 0.25 M due to stirring issues during the 
deprotonation step. After deciding on 0.25 M as the optimal concentration, a time study was 
done to see how long the reaction needed to go to completion. An aliquot from the reaction was 
checked every 30 minutes by LC-MS to see if any of the phosphonium salt remained. At the 3-
hour mark there seemed to be no remaining starting material and an 1H NMR was taken (Table 
2.1 entry 4). Our attention was then switched to the equivalents of thiol nucleophile needed 
(Table 2.1 entries 5-6). The yields were all similar at 1.5, 1.25 and 1.1 equivalents, but it was 
evident that a slight excess was beneficial. Entry 6 shows the optimal conditions that were 
decided on for further substrate evaluation. 
2.2.2 Thiol Nucleophile Scope 
 A range of alkyl thiols with various steric and electronic properties were reacted with 
phosphonium salt 1a (Table 2.2). Primary benzylic and heterobenzylic thiols formed their 
respective thioethers in good yields (2a & 2b). Next, steric properties were examined with a 
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secondary pyranthiol as well as a tertiary tert-butyl thiol (2c & 2d). Both thiols accommodated 
the reaction well, showing us that the coupling method is not overly sensitive to the steric 
features of the thiolate. The thiol proved to be relatively chemoselective over an alcohol and a 
carbamate by forming thioethers 2e and 2f in decent yield. Since saturated amine heterocycles 
are common motifs in pharmaceuticals we decided to see how well a thiol on a boc-protected 
piperidine as well as a pyrrolidine-thiol withstood the C-S bond construction reaction; both 
heterocyclic thiols proved to be excellent substrates for this reaction (2g & 2h). Finally, we 
wanted to see if we could couple an amino acid to 2-phenylpyridine. Unprotected cysteine did 
not form any of the desired product, likely due to salt decomposition by the free amine and 
electrophilic competition from the amide group. However, when the amine functionality is 
protected as a carbamate and the amide group is derivatized to a morpholine amide we were able 
to isolate a coupled product (2i), albeit in lower yield. 
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Table 2.2: C-S bond formation: Thiol Scope. Isolated yields are shown. Typical reaction 
conditions: 1a (0.5 mmol), thiol (0.55 mmol), NaH (0.55 mmol) and THF (2.0 mL).
 
 
2.2.3 Azaarene Scope 
 Next, we looked at various pyridines and diazines to see how different substitution 
patterns effected their reactivity. First, we looked at pyridines that contained SNAr active 
halogens at the 2-position and a triphenyl phosphonium salt at the 4-position (Table 2.3). We 
wanted to see if the coupling pathway via the phosphonium ion would outcompete the SNAr 
pathway via the halide. Each of these 2-halide pyridines were first converted into their respective 
phosphonium salts and those yields are shown in parenthesis. In each case (2i-2k), the 
phosphonium ion was able to out compete the SNAr displacement. Substrate 2j contains a 2-
flouro substituent and gave the lowest yield for 4-position thioether formation. Another 
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byproduct of this reaction that was observed by crude 1H NMR and LC-MS was the double 
addition product 2j’ where the thiolate added in at both the 2- and 4-postions. Since fluorine is 
the most SNAr active halogen, this makes sense that the excess thiol would add in to the 2-
position after fully reacting with the phosphonium ion at the 4-position. The other two substrates 
(2k & 2l), did not show any of this double addition product and were isolated in good yield. All 
these 2-halo phosphonium salts did not show any signs of forming product 2m where the SNAr 
pathway would have been more competitive than the intended phosphonium ion coupling 
pathway. These results were particularly exciting because since the thiolate prefers reacting with 
the phosphonium ion over the SNAr active halogen, the halogen can be used for further 
derivatization in subsequent metal catalyzed cross couplings or SNAr reactions. 
Table 2.3: Competition experiments for SNAr vs. phosphonium ion coupling. Isolated yields for 
phosphonium salt formation are shown in parentheses and isolated yields of the coupled product 




 Next, we looked at other substitution patterns on the nitrogen heterocycle to see how 
different steric and electronic properties effects the transformation (Table 2.4). Entry 2n shows 
that sterically bulky groups at the 3-position can be withstood as 3-phenylpyridine formed the 
thioether in good yield. A 2,3-substitution pattern can also be tolerated since tetrahydroquinoline 
worked well in the C-S bond forming reaction (2o). 2-2-bipyridine underwent the etherification 
to form 2p in moderate yield. A 3,4,5-trisubstituted pyridine (2q) was forged in excellent yield 
using this protocol. Diazines also proved to be particularly responsive to this thioetherification 
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method. The thioether formed quite well on a pyrimidine (2r), however, minor amounts of 
regioisomer at the 2-position of the pyrimidine were observed during phosphonium salt 
formation. Quinoxaline, on the other hand, was able to form the thioether 2s with complete 
regiocontrol. 
Table 2.4: C-S Bond-Formation: Azaarene Scope; Isolated yields of the corresponding 
phosphonium salt are shown in parentheses and isolated yields of the final product are also 
shown. Typical reaction conditions: Heterocyclic Phosphonium salt (0.5 mmol), benzyl thiol 




 As stated earlier, our goal was to make this heterocyclic functionalization method 
attractive to medicinal chemists, so we decided to subject the two-step protocol to late-stage 
derivatization of some complex pharmaceuticals (Table 2.5). Etoricoxib is a pain reliever used to 
treat Rheumatoid arthritis and can form the C-S bond via the phosphonium salt in reasonable 
yield (2t). The commonly used antihistamine Claritin, also known as Loratadine, can also be 
form the thioether functionality (2u). A thioether moiety was also able to be installed in 
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moderate yield at the two position of benzyl-protected cinchonidine where the 4-position of the 
quinoline is blocked (2v). 
Table 2.5: Late-stage thioetherification of pharmaceuticals. Isolated yields of phosphonium salt 
formation are shown in parentheses and isolated yields of the final product are also shown. 
 
 
2.2.4 Initial Studies on Sulfinate and Sulfonamide Addition to Heterocyclic phosphonium 
salts 
 Sulfones are another example of heterocyclic functionalities that are commonly found in 
therapeutics.9 We were curious to see how sulfinate nucleophiles would react with our 
heterocyclic phosphonium salts. An initial trial was conducted and showed considerable promise 
for this reaction going forward. First, the reaction was ran in THF (0.5 M) at 60 ºC for 48 hours 
using 1.5 equivalents of sodium methane sulfinate and 15-crown-5 (Figure 2.5). There were 
some solubility issues when there was no crown ether used and no product was formed. It is 
believed that the crown ether helps with the transformation by active as a phase transfer catalyst 
as well as making the sulfinate more nucleophilic via sodium trapping. The coupling reaction 
was then ran in in 1,4-dioxane at a higher temperature of 100 ºC and the yield improved. 
Although the isolated yield is low right now, we are able to clearly form the intended product. 




Figure 2.5: Initial trials of sulfinate addition to heterocyclic phosphoniums salts. Yields shown 
are isolated unless otherwise noted. 
 
2.3 Summary 
 It has been shown that heteroaryl thioethers can be selectively assembled on pyridines 
and diazines via nucleophilic attack of heterocyclic phosphonium salts. The reaction showed to 
withstand a variety of thiolate nucleophiles ranging in steric and electronic properties. A couple 
of thiols protruding from amine heterocycles and an amino acid derivative were also shown to 
undergo C-S bond formation in reasonable yields. The heterocyclic portion proved to be more 
competitive for thioether formation at the 4-position via the phosphonium salt when an SNAr 
active halogen was present at the 2-position. The selective formation of thioethers on pyridines 
with variable substation patterns as well as a couple of diazines were also shown. Bioactive 
molecules proved responsive to this C-S bond forming strategy, showing that this method is 
viable for late-stage formation of heteroaryl thioethers on pharmaceuticals. Furthermore, initial 
results for the selective formation of heteroaryl sulfones via heterocyclic phosphonium salts was 
communicated. Initial trials for using sulfonamides were also conducted, but no product 
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CHAPTER 3: COUPLING AROMATIC HETERONUCLEOPHILES TO AZINES AND 
DIAZINES VIA HETEROCYCLIC PHOSPHONIUM SALTS 
3.1 Introduction 
 For the class of nucleophiles described in this chapter we coined the term “aromatic 
heteronucleophiles” to group them together.1 Aromatic heteronucleophiles contain an aromatic 
ring and the nucleophilic portion is a heteroatom. The nucleophilic heteroatom can either be 
situated within the ring system (endocyclic) or outside of the ring system (exocyclic). As shown 
in figure 3.1, some examples of endocyclic aromatic heteronucleophiles include pyrroles, 
imidazoles, pyrazoles and triazoles. Phenols, thiophenols, benzneneselenols and anilines are all 
examples exocyclic aromatic heteronucleophiles.  
 
Fig. 3.1: Representative examples of Exocyclic and Endocyclic Aromatic Heteronucleophiles 
 
 Aromatic heteronucleophiles are fundamental building blocks commonly found coupled 
to other heterocycles in drug-like molecules.2 Figure 3.2 shows these types of linkages present in 
four different chemotherapy drugs. These motifs are often valuable pharmacophores in drug 




Fig. 3.2: Examples of Aromatic heteronucleophile linkages to pyridines and quinolines in 
chemotherapy drugs 
 
Traditionally, heteroatom-azine bonds are formed using SNAr or metal-catalyzed 
reactions, both of which typically initially require a heteroaryl-halide or -triflate functionality.3-5 
Metal catalyzed reactions are reliant on the oxidative addition of a metal catalyst into the pre-
installed halide or triflate group. The oxidative addition complex that is subsequently formed is 
intercepted by the aromatic heteronucleophile and can undergo reductive elimination to form the 
new carbon-heteroatom bond. A multitude of metal-oxidative addition complexes consisting of 
Palladium, Copper and Nickel are used for each different aromatic heteronucleophile. 
Consequently, these catalytic protocols also vary in their reaction conditions, bases and ligands 
required for maximum yield. We envisioned that heterocyclic phosphonium salts could serve as a 
more unified synthetic handle for the formation of these valuable carbon-heteroatom bonds 
(Figure 3.3). This strategy would allow for a simpler approach to the coupling of aromatic 
heteronucleophiles to azines and diazines by providing a much narrower set of reaction 
conditions. Another potential advantage of this method is that heterocyclic phosphonium salts 
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are bench-stable powders as opposed to reactive intermediates, which could potentially allow for 
easier access to a wide variety of complex drug derivatives in high-throughput screens.6  
 
Fig. 3.3: General reaction scheme for addition of aromatic heteronucleophiles to heterocyclic 
phosphonium salts 
 
Furthermore, this method is promising for the coupling of heteronucleophiles to complex 
N-heterocycles where either the halogen precursor can’t easily be installed, or the heterocycle 
contains polar functional groups which are typically problematic for metal-catalyzed strategies.7 
Already knowing that we have the ability to form the phosphonium ion late-stage on complex 
azines and pharmaceuticals,8 it made sense to look into coupling this diverse range of 
heteronucleophiles.  
3.2 Results 
3.2.1 Optimization of Phenol Coupling 
 We realized quickly that these aromatic heteronucleophiles were not able to be coupled to 
azines via the phosphonium salt under the conditions that were reported for the alkyl thiols in 
chapter 2 (Table 3.1 entry 1).9 When the reaction fails to undergo the desired coupling, we notice 
that the salt decomposes to the C-H product 3b’. The source of this undesired pathway remains 





Table 3.1: Optimization of p-methoxy phenol coupling to phosphonium salts. All reactions ran 
using 0.2 mmol of 1a and the equivs of NaH, 15-crown-5 and p-methoxyphenol match. [a]Yields 
determined by 1H NMR of the crude mixture using 1,3,5-trimethoxybenzene as an internal 
standard. 
 











1 rt THF 1.1 none 0 87 
2 rt THF 1.1 15-crown-5 3 83 
3 rt THF 1.5 none 0 78 
4 40 THF 1.5 none 36 62 
5 40 THF 1.1 15-crown-5 36 59 
6 40 THF 1.5 15-crown-5 49 40 
7 60 THF 1.5 15-crown-5 87 6 
8 40 DME 1.5 15-crown-5 76 21 
9 40 1,4-dioxane 1.5 15-crown-5 14 81 
10 40 DMF 1.5 None 1 91 
 
We began to look further into adjusting the reaction conditions of para-methoxyphenol 
with 2-phenyl pyridine phosphonium salt (1a) to see if we could get any desired coupling. We 
looked to see if adding a stoichiometric amount of a crown ether to the reaction could help promote 
the desired pathway at room temperature (Table 3.1 entry 2), however, this additive only provided 
a small amount of product formation with the C-H pathway still taking precedent. Increasing the 
equivalents of phenol from 1.1 to 1.5 in entry 3 also showed no promise. To our delight, elevating 
the reaction temperature beyond ambient conditions provided enough energy to the system to 
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slightly subdue the C-H pathway and afford some of the desired coupled product 3b (Table 3.1 
entry 4). Adding 15-crown-5 in entry 6 improved the yield of the desired diaryl ether further. 
Increasing the temperature further to 60 ºC showed the most promising result for this coupling 
reaction (Table 3.1 entry 7). A couple of other common solvents were screened for compatibility 
with the reaction (Table 3.1 entries 8-10) and only dimethoxyethane (DME) showed reasonable 
promise at 40 ºC. We decided to continue with the reaction conditions slated out in entry 7 as our 
most general method, but also kept in mind that DME could also be substituted as the solvent when 
needed. 
3.2.2 Exocyclic Aromatic Heteronucleophile Scopes 
 With a generic set of reaction conditions in place, we began to study how varying the 
functionality on the phenol ring effected the desired coupling pathway (Table 3.4). Phenol was 
able to be coupled to 2-phenyl pyridine in decent yield (3a). Methoxy groups are tolerated at 
both the para- and ortho- positions (3b & 3c). Admittedly, electron withdrawing groups tend to 
decrease the yield of the coupling reaction; however, para-iodo phenol was isolated (3d) in 
moderate yield with the halide still intact. A meta-bromo-para-methoxyphenol (3e) was also 
feasible, showing that another halogen that would prove reactive in metal-catalyzed reactions 
could be tolerated under our protocol. It is also noted that this phenol showed a higher yield 
when ran in DME at 80 ºC. Tetrahydro-2-napthol 3f showed excellent coupling capability with 
this method. Acetaminophen (Tylenol) reacted through its phenol oxygen with reasonable 
coupled product being formed (3g). The naturally occurring amino acid Tyrosine was coupled to 
2-phenyl pyridine in modest yield after boc-protection of its amino group (3h). The coupling of 
benzeneselenol to 2-phenyl pyridine was superlative (3i), providing another example of a 
tolerable endocyclic aromatic heteronucleophile. 
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Table 3.4: Phenol nucleophile scope. All yields shown are isolated. [a] ran in DME. 
 
 
 Next, our attention turned to the functional alteration on the thiophenol moiety (Table 
3.5). Thiophenol (3j) proved to be more efficient in this coupling protocol compared to its 
oxygen equivalent. All of these thiophenols were tested with and without the use of 15-crown-5 
and if the 1H NMR yields were within 5% of each other, then the one without the additive was 
isolated. Ortho-methoxythiophenol (3k) was one example of a thiophenol that coupled great 
without the use of the crown ether. A range of halogens at the ortho- and para- positions tolerated 
the coupling protocol (3l-n). A boronic pinnacle ester also withstood this coupling protocol (3o), 
providing another example of a valuable functional handle that remains unscathed in this 
procedure. 3p & 3q show the tolerability of meta substituents. Coupling of a sterically hindered 
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2,6-disubstituted thiophenol 3r was also cooperative. Substrate 3s showed us that the exocyclic 
nucleophile can protrude from a heteroaromatic compound as this thiophene worked well. 
Table 3.5: Thiophenol Nucleophile scope. All yields shown are isolated. [b]Substrates showed 





3k, X = OMe, 80%[b]
























3m, X = F, 78%[b]




 The last class of endocyclic aromatic heteronucleophiles in which we modified 
substitution patterns on the nucleophile were anilines (Table 3.6). These nucleophiles require a 
modified reaction protocol; the aniline is deprotonated at 0 ºC using n-butyl lithium, after stirring 
for 30 mins the phosphonium salt is added and the reaction is warmed to room temperature. 
These reactions occur very quickly and are typically done within 1 hour. One caveat of this class 
of nucleophiles, however, is that the nitrogen atom must be alkylated for the desired coupling to 
occur. When aniline is subjected to this coupling protocol, we observe no formation of the 
desired product (3t). Instead we see a mass at 354.2 m/z on the LC-MS, which we attribute to 
iminophosphorane 3t’. Figure 3.4 demonstrates our hypothesis for the salt decomposition 




Figure 3.4: Proposed decomposition pathway for aniline as a nucleophile. m/z LRMS (ESI + 
APCI) found [M + H]+ 354.2, C24H21NP+ requires 354.1. 
 We assumed that we could avoid this undesired reaction if we substituted the aniline 
nitrogen with an alkyl group, forbidding the deprotonation step and hopefully allowing for ligand 
coupling to occur. Our hypothesis proved to be correct as we were able to couple N-
methylaniline to 2-phenyl pyridine in excellent yield (3u). An ortho-ethoxy substituent was also 
tolerated on the N-methylaniline (3v). A benzyl protection strategy was also employed, albeit in 
lower yield (3w). Indolines 3x & 3w were also compatible coupling partners under these 
conditions.  




 After proving the validity of the these exocyclic aromatic heteronucleophiles as 
competent coupling partners to a simple pyridine, we decided to look at the scope of heterocyclic 
phosphonium salts that could be tolerated. All these phosphonium salts were prepared from their 
C-H precursors in the protocol described in chapter 18a with complete control of regioselectivity 
in most cases (refer to appendix 2 for specific reaction details).  
 Para-methoxyphenol was kept constant as the coupling partner for a variety of azaarenes 
in table 3.7. Mono-substituted pyridines at the 3- and 4- positions were tolerated well (3z & 3aa). 
Steric hindrance on a 3,5-disubstituted pyridine proved to be no issue for phenol coupling to 
occur (3ab). 4-methyl quinoline also proved to be a compatible heterocycle with moderate C-O 
bond formation at the 2-position (3ac). A di-substituted pyrimidine equipped with a methyl 
thioether at the 2-position and a bromine at the 5- worked great with para-methoxy phenol (3ad). 
Quinoxoline 3ae also proved to be a competent heterocycle for this coupling strategy. 





 Thiophenol was also subjected to a range of heterocyclic phosphonium salts and the 
results are shown in table 3.8. C-S bond formation occurred on both 3-phenylpyridine (3af) as 
well as 2-methoxypyridine (3ag). Sterics were also no trouble for the thiophenol as a 3,5-
disubstituted pyridine was capable for coupling (3ah). A 2-3-disubstition pattern was also 
tolerated to form the diaryl-thioether 3ai. A quinoline equipped with a thiophene and a 
trifluoromethyl group selectively formed the C-S bond at the 2-position (3aj). A monosubstituted 
pyrimidine phosphonium salt was also compatible with thiophenol (3ak). 





TfO Thiophenol (1.5 eq.)
NaH, 15-Crown-5





















3af, 77% 3ag, 45% 3ah, 63%
3ai, 77%[a] 3aj, 74% 3ak, 66%  
 
 N-methylanilines proved to be difficult to find compatible coupling partners for. 2-
position substituents work well for the reaction (3al), however substituents at the 3- and 5- 
positions on the pyridine are troublesome (3ao). A cyano group was the only 3-position 
functionality that allowed for the desired coupling reaction to occur as shown in examples 3am 








TfO N-methylaniline (1.5 eq.)
n-BuLi, THF





















3al, 82% 3am, 81% 3an, 69% 3ao, 0%  
 
3.2.3 Endocyclic Aromatic Heteronucleophile Scopes 
 After having success in coupling a variety of exocyclic aromatic heteronucleophiles, we 
wanted to see how successful this strategy was towards nucleophiles where the nucleophilic 
atom is situated within the aromatic ring system. We used a similar strategy employed in the 
previous reactions where the nucleophile is first deprotonated at 0 ºC then warmed to 60 ºC after 
the addition of the phosphonium salt. An array of different azoles was studied for their 
compatibility with this coupling protocol (Table 3.10). 
Table 3.10: Endocyclic aromatic heteronucleophiles scope. All yields shown are isolated. [b] KH 




 We were delighted to find that pyrrole formed a C-N bond at the 4-position of 2-
phenylpyridine via the phosphonium salt in excellent yield (3ap). This exciting discovery was 
followed up with pyrazole also showing considerable coupling capability (3aq). Imidazole 
proved to be more precarious under these coupling conditions. However, we were able to 
improve the coupling of this electron deficient ring by switching to potassium hydride and using 
18-crown-6 as the crown ether (3ar). We assume that enlarging the anion and trapping it with 
it’s corresponding crown ether allows for a weaker ionic interaction with the nitrogen anion, 
allowing for increased nucleophilicity and thus better reactivity with the phosphonium. KHMDS 
was also employed for this strategy, but no product formation was detected and instead it 
triggered the C-H pathway. 4-bromopyrazole worked well for this reaction (3as) and left the 
halogen in tact for further functionalization. A sterically bulky 3,5-dimethylpyrazole also proved 
to be compatible (3at). A phenylimidazole also formed the C-N bond using the KH conditions 
(3au). We were surprised to see that indole (3av) was not suitable as a coupling partner. We 
currently believe that there might be an unfavorable steric interaction with the 7-position C-H 
bond that inhibits the desired coupling. Triazoles also proved to be incompatible for C-N bond 
formation (3aw), presumably due to its electron deficient nature.  
 Having found a few endocyclic aromatic heteronucleophiles that were appropriate for our 
coupling strategy, we began to look at altering the heterocyclic phosphonium salt (table 3.11). 
Pyrrole was able to be coupled to 2,2-bipyridine in moderate yield (3ax). Sterically bulky groups 
at the 3- and 5-positions of the pyridine proved to hinder the coupling of pyrrole as shown in 
substrate 3ay. A phosphonium salt at the 4-position of 5-(4-methoxyphenyl)pyrimidine, on the 
other hand, worked great in forming the C-N bond (3az). By blocking the 4-position of a 
pyridine with a trifluoromethyl group, we were able to selectively form the phosphonium salt at 
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the 2-position and subsequently couple pyrrole, pyrazole and imidazole (3ba-3bc). It should be 
noted, however, that substrate 3bb was volatile so it wasn’t able to be isolated. Instead, our 
evidence for the desired C-N bond formation was based on LC-MS and crude 1H NMR data 
(refer to appendix 2 for more details). 
Table 3.11: Azaarene scope for pyrroles, pyrazole and imidazole. All yields shown are isolated 
unless otherwise noted. [c]Product was volatile.  
 
 
3.2.4 Drug-like Fragments and Bioactive Molecules 
 The overarching goal of this project was to be able to couple these nucleophiles in late-
stage functionalization applications of bioactive molecules. We began this challenge by 
subjecting our phosphorous ion-mediated process to a series of complex pyridines and diazines 
that resemble the structures of bioactive molecules that could potentially be found in drug 
development programs (table 3.12). First, the C-H precursor of each of these drug-like fragments 
were constructed then subjected to the formation of a heterocyclic phosphonium salt (refer to 
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appendix 2). Our goal was to construct intricate fragments that contain functional groups that 
prove difficult for traditional methods, to further show how our method could be favorable in 
late-stage applications.  
Table 3.12: Scope of aromatic heteronucleophile addition to heterocyclic phosphonium salts on 
drug-like fragments. All yields shown are isolated from the coupling reaction. Some reactions 









































3bh, 37%  
A tripyridine system worked great in coupling a thiophenol (3bd), and thanks to the 3-
substituted pyridine reacting preferentially with triflic anhydride during phosphonium salt 
formation we were able to accomplish this C-S bond formation with complete site-selectivity.  A 
pyridine containing a benzhydryl center at the 2-position was successful in pyrrole coupling 
(2be). Another polyazine system proved compatible for thioether formation when we were able 
to couple thiophenol to the 4-position of a pyridine that also contained piperazine and quinoline 
motifs (3bf). Para-methoxyphenol was able to be coupled to a pyrimidine fragment containing a 
1,2-oxazole moiety (3bg). We used our recently disclosed site-selective switching strategy10 in 
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polyazine 3bh to selectively form the phosphonium on the pyrimidine ring and further couple N-
methylaniline to it. A quinoline fragment containing a dimethyl morpholine moiety proved 
worthy in coupling imidazole at the 2-position (2bi). 
With a representative group of successful coupling examples in place, we decided to turn 
our attention to employing our site-selective functionalization strategy on complex drugs and 
other bioactive molecules (table 3.13). A benzyl-protected version of the smoking cessation drug 
varenicline, also known as Chantix, contains a quinoxoline ring system that reacted well with 
para-methoxyphenol (3bj). Pyrrole was able to be coupled to benzyl-protected cinchonidine in 
moderate yield (3bk). Site-selectivity was further exploited in forming etoricoxib derivative 3bl. 
Loratidine, more commonly known as Claritin, forms the phosphonium salt with complete 
regioselectivity at the 4-position of it’s pyridine and proved to be an excellent coupling partner 
with thiophenol (3bm). An analogue of bepotastine was great for further derivatization to a to a 
selenoether (3bn). The prostate cancer drug abiraterone acetate was able to be coupled to a 
thiophenol to make 3bo in decent yield. A pesticide also proved competent as para-methoxy 
phenol reacted well with the phosphonium salt on pyriproxyfen (3bp). We were pleased to see 
that the complex cancer drug imatinib was successful in coupling a thiophenol (3bq), however 












Table 3.13: Scope of aromatic heteronucleophile addition to heterocyclic phosphonium salts on 
bioactive molecules. All yields shown are isolated. Some reactions required modified conditions 










































































3bq, 57% ; 6% Regioisomer





3.2.5 Novel Tyrosine Kinase Inhibitor Synthesis 
 Tyrosine kinase inhibitors (TKIs) are used for treatment of different kinds of cancer, 
including renal cell, gastrointestinal and hepatocellular cancers.11 The oldest and most commonly 
known TKI is imatinib, which is used to treat patients with myeloid leukemia. We were pleased 
to be able to derivatize imatinib (3bq) directly from a C-H bond in the active drug. TKIs can 
limit cell growth and proliferation by blocking intracellular pathways in malignant tumors and 
cancer cells. Specifically, they compete with adenosine triphosphate (ATP) at its binding domain 
which inhibits tyrosine kinases from participating in further cell-growth pathways.12 Since the 
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efficacy of these drugs depend on this competitive binding ability, the structure of these 
pharmaceuticals are intricate and slight derivatizations have the potential to increase its potency 
considerably. For example, Sorafenib and Regorafenib (fig. 3.2) are two FDA approved tyrosine 
kinase inhibitors and are very similar in structure with only one C-F bond differentiating them. 
Interestingly, they both serve separate oncogenic purposes as Sorafenib is used to treat kidney 
cancer and Regorafenib is used for advanced colon cancer. We found it very intriguing that one 

























Fig. 3.2: Examples of tyrosine kinase inhibitors containing a possible bond disconnection for our 
selective heterocycle functionalization strategy. 
 
To further demonstrate the utility of our reaction we wanted to attempt a complex 
convergent coupling strategy to construct a novel drug derivative that would prove difficult to 
make via traditional methods. We wanted to use our site-selective coupling strategy to create a 
unique scaffold that would be challenging to access through the conventional SNAr and metal-
catalyzed approaches. Our eye was caught by the scaffold of sorafenib and regorafenib because 
the phenolic C-O bond at the 4-position of the pyridine ring (highlighted in red in figure 3.2) was 




Fig. 3.3: Synthesis of a derivative of Sorafenib via nucleophilic addition to a heterocyclic 
phosphonium salt. All yields shown are isolated. 
 
 We began this convergent coupling strategy (figure 3.3) by first constructing the urea 
bond off the phenol ring. This was easily achieved by reacting isocyanate 3br with 4-
aminophenol in CH2Cl2. Compound 3bs was isolated and we had a phenol nucleophile that 
completely resembles the diaryl urea moiety of sorafenib. Next, we needed to induce some 
novelty into our derivative by introducing some functionality onto the heterocycle that would 
prove difficult for halide introduction at the 4-position. We believed that a cyclopropyl ring at 
the 5-position would be an excellent candidate. We employed a Negishi cross coupling reaction 
to install the cyclopropyl ring (3bt). We were able to isolate just enough of this pyridine to carry 
on to the phosphonium salt reaction, which worked well to selectively form the phosphonium at 
the 4-position (3bu). With our nucleophile and phosphonium handle prepared, we began to look 
at a variety of coupling conditions to construct the C-O bond. It was found that the reaction 
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worked best in DME as the diaryl urea suffered some major solubility issues in THF. 
Nevertheless, we were able to successfully isolate this novel tyrosine kinase inhibitor derivative 
in 40% yield (3bv). 
 
Fig. 3.4: Potential route for amide bond formation on sorafenib derivative. 
 
 Notably, we had to use a methyl ester at the 2-position of the pyridine instead of a methyl 
amide due to amides behaving poorly during the phosphonium salt formation reaction. This 
amide functionality in sorafenib and regorafenib is actually very important for the inhibition of 
ATP binding in tyrosine kinases. The pyridine nitrogen and amide N-H bond participate in ‘type 
II binding’ where they occupy an allosteric site and the rest of the molecule is perfectly 
positioned to block the ATP binding site.13 The amide N-H bond acts as a hydrogen bond donor 
during this allosteric binding interaction, so we found it important to disclose a possible route for 
this conversion. The methyl ester should be fairly activated for reactivity with an amine 
nucleophile because of the electron withdrawing capabilities of the pyridine ring. We imagined 
that methyl amine could undergo amidation in methanol at high temperatures (figure 3.4). 
However, due to lack of enough material, we were unable to test this hypothesis. 
3.3 Summary 
 To summarize, we were able to show that seven different classes of aromatic 
heteronucleophiles can serve as competent coupling partners with heterocyclic phosphonium 
salts to regioselectivity form C-O, C-S, C-Se and C-N bonds on pyridines and diazines. We 
believe that our simplified functionalization method, which allows for the use of bench stable 
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intermediates, is advantageous over traditional metal catalyzed cross couplings and SNAr 
reactions. This approach is feasible for late-stage functionalization of complex drug molecules 
and could allow for quicker access to valuable derivatives without having to worry about the 
installation of halogen precursors. This approach also allowed for the construction of a novel 
tyrosine kinase inhibitor via a convergent reaction between two complex coupling partners. This 
simple procedure should prove valuable to medicinal chemists due to our array of evidence of its 
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APPENDIX 1: CHAPTER 2 EXPERIMENTAL 
General considerations: 
Unless stated, all starting materials are either known compounds or were obtained from 
commercial sources and used without purification. Reactions were carried out under an 
inert atmosphere of nitrogen unless stated. Reaction progress was monitored by TLC, 1H 
NMR spectra taken from reaction samples or LCMS analysis. Tetrahydrofuran (THF), 
toluene, diethyl ether and dichloromethane were degassed and passed through a solvent 
purification system (alumina columns). 1,2-Dichloroethane (DCE), 1,4-dioxane, 
chloroform, chlorobenzene and acetone were purchased anhydrous from Sigma Aldrich 
chemical company. Flash chromatography was performed on Silicycle silica gel (Silaflash 
P60 (230-400 mesh)) with the indicated solvent system. 
1H NMR spectra were recorded at ambient temperature on a Varian 400 MR spectrometer 
(400 MHz) or an Agilent Inova 400 (400 MHz) spectrometer. Chemical shifts () are 
reported in ppm and quoted to the nearest 0.01 ppm relative to the residual protons in CDCl3 
(7.26 ppm), C6D6 (7.16 ppm), (CD3)2SO (2.50 ppm), CD3OD (3.31 ppm) or CD3CN (1.94 
ppm) and coupling constants (J) are quoted in Hertz (Hz). Data are reported as follows: 
Chemical shift (number of protons, multiplicity, coupling constants). Coupling constants 
were quoted to the nearest 0.1 Hz and multiplicity reported according to the following 
convention: s - singlet, d - doublet, t - triplet, q - quartet, qn - quintet, sext - sextet, sp - 
septet, m - multiplet, br - broad. 13C NMR spectra were recorded at ambient temperature 
on a Varian 400 MR spectrometer (100 MHz) or an Agilent Inova 400 (100 MHz) 
spectrometer. 
Chemical shift () was measured in ppm and quoted to the nearest 0.1 ppm relative to the 
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residual solvent peaks. 




To a solution of 5-(3- fluorophenyl)nicotinonitrile (1.29 g, 6.51 mmol) in CH2Cl2 (65 mL) at 
78 oC was added Tf2O (1.09  mL, 6.51  mmol) dropwise over 5 min. The reaction was stirred 
for 30 min before PPh3 (1.88 g, 7.16 mmol) was added in one portion. The reaction was 
subjected to three rapid cycles of vacuum/nitrogen backfill and stirred for a further 30 min at 
78 oC. DBU (0.97 mL, 6.51 mmol) was added dropwise, the cooling bath was removed, and 
the reaction was allowed to warm to room temperature while stirring (approximately 15 min). 
The reaction mixture was quenched with H2O (65 mL) and the mixture transferred to a 
separatory funnel. The mixture was diluted with CH2Cl2 and the resulting organic layer was 
washed three times with H2O. The organic layer was dried (MgSO4), filtered and concentrated 
to approximately 10 mL. The concentrated solution was added to an excess of Et2O (20 oC) 
and then placed in a 20 oC refrigerator for around 1 h. The resulting suspension was filtered 
on a frit, the solid washed with chilled Et2O ( 20 oC) and dried in vacuo to provide the title 
compound (3.00 g, 4.93 mmol, 76% yield) as a white solid. mp 98-112 oC; IR max/cm-1 (film): 
3065, 1585, 1439, 1260, 1150, 1099, 1029, 997, 719, 684, 636, 549; 1H NMR (400 MHz, 
CDCl3) d: 9.10 (1H, dd, J  = 4.9, 1.2 Hz), 8.83 (1H, dd, J = 5.5, 1.1 Hz), 7.92-7.44 (15H, m), 
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7.02-6.92 (1H, m), 6.84-6.73 (2H, m), 6.70 (1H, d,  J  = 8.9  Hz);  13C  NMR (100 MHz, 
CDCl3) d: 162.59 (d, J = 247.8 Hz), 152.82, 147.29, 140.07, 137.63  (d, J = 7.9  Hz), 135.63, 
130.31  (d, J = 8.4  Hz), 128.95, 128.72, 127.93,  125.41  (d,  J = 3.1  Hz),  116.68  (d,  J = 
22.5  Hz),  115.98  (d, J = 21.0 Hz), 115.08; 19F NMR (365 MHz, CDCl3), -78.1; 31P NMR 
(162 MHz, CDCl3) 21.4; m/z HRMS (DART) found [M-OTf]+ 459.1425, C30H21FN2P+ 
requires 459.1421. 
Triphenyl(quinoxalin-2-yl)phosphonium trifluoromethanesulfonate     
 
To a solution of quinoxaline (52 mg, 0.40 mmol) in CH2Cl2 (4 mL) at -78 oC was added Tf2O 
(67 L, 0.40 mmol) dropwise over 5 min. The reaction was stirred for 30 min before PPh3 
(113 mg, 0.44 mmol) and NaOAc (50 mg, 0.60 mmol) were added in one portion. The 
reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and stirred for a 
further 30 min at -78 oC before being heated at 40 oC for 1 h. DBU (60 mL, 0.40 mmol) was 
added dropwise at room temperature, and the reaction was stirred for a further hour at 40 oC. 
The reaction mixture was quenched with H2O (10 mL) and the mixture transferred to a 
separatory funnel. The mixture was diluted with CH2Cl2 and the resulting organic layer was 
washed three times with H2O. The organic layer was dried (MgSO4), filtered and concentrated 
to approximately 10 mL. The concentrated solution was added to an excess of Et2O (20 oC) 
and then placed in a 20 oC refrigerator for around 12 h. The resulting suspension was filtered, 
dissolved in 10 mL CH2Cl2 and the precipitation process was repeated. The resulting solid 
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was filtered on a frit and dried in vacuo to provide the title compound (138 mg, 0.26 mmol, 
64% yield) as a white solid. mp 130-132 oC; IR max/cm—1 (film): 3063, 2360, 1484, 1438, 
1262, 1109, 1030, 634; 1H NMR (400 MHz, CDCl3) d: 8.99 (1H, s), 8.27-8.22 (2H, m), 8.09-
8.01 (2H, m), 7.93-7.90 (3H, m), 7.79-7.72 (12H, m); 13C NMR (100 MHz, CDCl3) : 145.86 
(d, J = 25.4 Hz), 143.38 (d, J = 2.8 Hz), 142.70 (d, J = 17.3 Hz), 140.83 (d, J = 111.6 Hz), 
136.16 (d, J = 3.1 Hz), 134.98, 134.66 (d, J = 10.5 Hz), 133.08, 130.86 (d, J = 13.0 Hz), 130.19 
(d, J = 2.0 Hz), 129.85 (d, J = 2.3 Hz), 120.76 (q, J = 319.5 Hz), 116.03 (d, J = 88.1 Hz); 19F 
NMR (365 MHz, CDCl3) : 78.17; 31P NMR (162 MHz, CDCl3) : 13.54; m/z HRMS 




To a solution of 5-chloro-6’-methyl-3-(4-(methylsulfonyl)phenyl)-2,3’-bipyridine  (384 
mg, 1.07 mmol) in CH2Cl2 (11  mL) at -78 oC was added Tf2O (180 L, 1.07 mmol) dropwise 
over 5 min. The reaction was stirred for 30 min before PPh3 (309 mg, 
1.18 mmol) and NaOAc (88 mg, 1.07 mmol) were added in one portion. The reaction was 
subjected to three rapid cycles of vacuum/nitrogen backfill and stirred for a further 30 min 
at -78 oC. DBU (160 L, 1.07 mmol) was added dropwise, the cooling bath was removed 
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and the reaction was allowed to warm to room temperature while stirring (approximately 
15 min). The reaction mixture was quenched with H2O (30 mL) and the mixture 
transferred to a separatory funnel. The mixture was diluted with CH2Cl2 and the resulting 
organic layer was washed three times with H2O. The organic layer was dried (MgSO4), 
filtered and concentrated to approximately 10 mL. The concentrated solution was added 
to an excess of Et2O (20 oC) and then placed in a 20 oC refrigerator 1 h. The resulting 
solid was filtered on a frit and dried in vacuo to provide the title compound (603 mg, 0.78 
mmol, 73% yield) as a white solid. mp 157-163 oC; IR max/cm-1 (film): 3062, 1709, 1577, 
1542, 1485, 1436, 1311, 1261, 1223,  1150, 1101, 1030, 921,  888,  715, 690, 636; 1H NMR 
(400 MHz, CDCl3) : 8.28 (1H, d, J = 7.1 Hz), 8.10 (2H, d, J = 8.2 Hz, H6), 7.86-7.62 
(16H, m), 7.51-7.45 (3H, m), 7.20 (1H, d, J = 16.5 Hz), 3.14 (3H, s),  2.54 (3H, s); 13C  
NMR (100 MHz, CDCl3) : 160.84 (d, J = 11.2 Hz), 152.42 (d, J = 7.3 Hz), 147.53 (d, J 
= 2.2 Hz), 146.09, 141.53,  141.02,  138.92,  135.62,  134.84  (d, J = 2.9  Hz),  134.17   (d, 
J = 10.0 Hz), 133.29 (d, J = 3.6 Hz), 132.10, 130.76 (d, J = 10.2 Hz), 130.03 (d, J = 13.1 
Hz), 129.86, 128.55, 128.19 (d, J = 86.2 Hz), 120.77 (q, J = 321.1 Hz), 119.34 (d, J = 
91.8 Hz), 43.96, 24.55; 19F NMR (365 MHz, CDCl3) : - 78.14; 31P NMR (162 MHz, 
CDCl3) : (162 MHz, CDCl3) : 25.54; m/z LRMS (ESI + APCI) found [M-OTf]+ 619.2, 
C36H29N2O2PS+ requires 619.1. 
General procedure for the thiol addition reaction to form heteroaryl thioethers 
(2a-2v): 
An oven dried 8 mL vial with a septa cap was charged with sodium hydride (60% dispersion 
in mineral oil, 1.1 equiv) and placed under a nitrogen atmosphere. THF (0.25 M) was added, 
the sus- pension was cooled to 0 oC and the thiol (1.1 equiv) was added dropwise over 5 min 
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(if the thiol was a solid or viscous liquid, it was added as a 0.5 M solution in THF to an 
equivalent volume 0.5 M solution of NaH in THF). The resulting thick slurry was stirred for 
30 min at 0 oC before the septa cap was briefly removed and the phosphonium salt (1.0 equiv) 
was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen 
back- fill, the ice bath removed, and the reaction stirred for 3 h while warming to room 
temperature. The reaction was quenched with H2O, the aqueous layer was separated and 
extracted with CH2Cl2 (3x). The combined organic extracts were washed with a saturated 
aqueous solution of brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography under the stated conditions to provide the heteroaryl 
thioether product. 
4-(benzylthio)-2-phenylpyridine (2a)   
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and THF (2.0 mL). Flash 
column chromatography (silica gel: 15% EtOAc in hexanes to 10% EtOAc in hexanes) 
afforded the title compound (2a) as a white powder (128 mg, 0.46 mmol, 92% yield). mp 48-
52 oC; IR max/ cm-1 (film): 3060, 3040, 3027, 2922, 1560, 1533,  1495,  1455,  1377, 770, 
709; 1H NMR (400 MHz, CDCl3) : 8.47 (1H, d, J 5.3 Hz), 7.90 (2H, d,  J = 7.7  Hz), 7.54  
(1H, m), 7.49-7.27  (8H, m), 7.08  (1H, dd, J = 5.2, 1.7 Hz), 4.27 (2H, s); 13C NMR (100 MHz, 
CDCl3) : 157.27, 149.50, 149.16, 139.07, 135.73, 129.11, 128.82, 128.72, 128.71 (2C), 
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 Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), pyridine-3-ylmethane thiol (62 L, 0.55 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and 
THF (2.0 mL). Flash column chromatography (silica gel: 50% EtOAc in hexanes) afforded 
the title compound (2b) as a yellow oil (104 mg, 0.38 mmol, 75% yield). IR max/cm-1 
(film): 3049, 2918, 1569, 1534, 1466, 1435, 1381, 772, 730, 693; 1H NMR (400 MHz, 
CDCl3) : 8.59 (1H, d, J = 4.7 Hz), 8.45 (1H, d, J = 5.4 Hz) 7.95-7.89 (2H, m), 7.70-7.63 
(2H, m), 7.51-7.37 (4H, m), 7.20 (1H, dd, J = 7.2, 4.9 Hz), 7.13 (1H, dd, J = 5.3, 0.7 Hz), 
4.41 (2H, s); 13C NMR (100 MHz, CDCl3) : 157.20, 156.64, 149.40, 149.09, 148.93, 
138.98, 137.00, 129.10, 128.70, 126.93, 122.86, 122.48, 119.26, 117.84, 37.48; m/z HRMS 









Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), tetrahydro-2H-pyran-4-thiol (63 L, 0.55 mmol), triphenyl(2-
phenylpyridin-4-yl) phosphonium trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and 
THF (2.0 mL). Flash column chromatography (silica gel, gradient elution: 40% EtOAc in 
hexanes) afforded the title compound (2c) as a white solid (92 mg, 0.37 mmol, 74% yield). mp 
62-64 oC; IR nmax/cm-1 (film): 3071, 2956, 2914, 2863, 2839, 1565,  1533,  1461, 1440, 1379, 
1126, 1083, 1007, 981, 818, 772, 698; 1H NMR (400 MHz, CDCl3) : 8.50 (1H, d, J      5.3 
Hz), 7.97-7.91 (2H, m), 7.57 (1H, d, J = 1.3 Hz), 7.50-7.38 (3H, m), 7.09 (1H, dd, J = 5.3, 1.7 
Hz), 4.00 (2H, dt, J = 11.9, 3.9 Hz), 3.66-3.49 (3H, m), 2.09-1.99 (2H, m), 1.83-1.70 (2H, m); 
13C NMR (100 MHz, CDCl3) : 157.57, 149.39, 147.62, 138.98, 129.19, 128.76, 126.96, 










Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), tert-butyl thiol (62 L, 0.55 mmol), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and THF (2.0 mL). Flash 
column chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound (2d) 
as a white crystalline solid (109 mg, 0.45 mmol, 90% yield). mp 56-62 oC; IR max/cm-1 (film): 
3042, 2976, 2967, 2955, 2921, 2856, 1568, 1533, 1463,  1443,  1375, 1364, 1161, 847,  775, 
686, 618;  1H NMR (400 MHz, CDCl3) : 8.6 (1H, d, J = 5.1 Hz), 7.99 (2H, d, J = 7.6 Hz), 
7.83 (1H, m), 7.52-7.40 (3H, m), 7.35 (1H, d, J = 5.0, 1.7 Hz), 1.41 (9H, s); 13C NMR (100 
MHz, CDCl3) : 157.55, 149.35, 144.77, 138.91, 129.17, 128.78, 128.20, 126.97, 126.90, 
47.08, 31.24; m/z HRMS (DART) found [M+H]+ 244.1169, C15H18NS+ requires 244.1154. 
3-((2-Phenylpyridin-4-yl)thio)propan-1-ol (2e)  
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), 3-mercaptopropan-1-ol (48 L, 0.55 mmol), triphenyl(2- 
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and 
THF (2.0 mL). Flash column chromatography (silica gel, dry load: 50% EtOAc in hexanes) 
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afforded the title compound (2e) as a yellow oil (111 mg, 0.45 mmol, 91% yield). IR max/cm-
1 (film): 3285 (br), 2923,  2850,  1571,  1533,  1465,  1444, 1382, 1056, 907, 773, 730, 694; 1H 
NMR (400 MHz, CDCl3) : 8.48 (1H, d, J = 5.3 Hz), 7.95  (2H, d, J =  7.7  Hz), 7.57  (1H, 
m), 7.50-7.38 (3H, m), 7.09 (1H, dd, J = 5.2, 1.3 Hz), 3.83 (2H, t, J = 6.1 Hz). 3.18 (2H, t, J 
= 7.1 Hz), 2.00 (2H, app t, J = 6.5 Hz); 13C NMR (100 MHz, CDCl3) : 157.26, 149.97, 148.97, 
139.03, 129.15, 128.73, 127.02, 119.02, 117.82, 60.74, 31.28, 27.21; m/z HRMS (DART) found 
[M+H]+ 246.0961, C14H16NOS+ requires 246.0947. 
Tert-butyl(2-((2-phenylpyridin-4-yl)thio)ethyl)carbamate (2f) 
 
 Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), tert-butyl(2-mercaptoethyl)carbamate (93 mL, 0.75 mmol), 
triphenyl(2- phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (1a, 283 mg, 0.50 
mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 30% EtOAc in hexanes) 
afforded the title compound (2f) as an off-white amorphous solid (102 mg, 0.31 mmol, 62% 
yield). IR max/cm-1 (film): 3343, 2976, 2930, 1699, 1571, 1534, 1506, 1365, 1251, 1164, 908, 
773, 730, 694; 1H NMR (400 MHz, CDCl3) : 8.47 (1H, d, J = 5.3 Hz), 7.98 (2H, d, J = 7.5 
Hz), 7.64 (1H, m), 7.48e7.34 (3H,  m),  7.10   (1H,  dd,  J  =  5.3,  1.7   Hz),  3.43  (2H,  q,  J 
= 6.6 Hz). 3.17 (2H, t, J = 6.8 Hz), 2.15 (1H, s). 1.43 (9H, s); 13C NMR (100 MHz, CDCl3) : 
157.41, 149.22, 148.73, 138.96, 129.13, 128.67, 127.06, 119.13, 117.69, 79.72, 53.42, 39.69, 
30.59, 28.34; m/z HRMS (DART) found [M+H]+ 331.1488, C18H23N2O2S+ requires 331.1475. 
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Tert-butyl (S)-3-(((2-phenylpyridin-4-yl)thio)methyl)piperidine-1-carboxylate (2g) 
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), tert-butyl (S)-3-(mercaptomethyl)piperidine-1-carboxylate (127 
mg, 0.55 mmol in 1 mL of THF), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 30% EtOAc in hexanes) afforded the title compound (2g) as a 
yellow oil (167 mg, 0.44 mmol, 87% yield). IR max/cm-1 (film): 2975, 2929, 2854, 1681, 
1571, 1535, 1424, 1365, 1261, 1241, 1163, 907, 772, 728, 694; 1H NMR (400 MHz, CDCl3) 
: 8.49 (1H, 1H, dd, J 5.3, 0.5 Hz), 7.97-7.92 (2H, m), 7.53 (1H, dd, J = 1.8, 0.6 Hz), 7.50-
7.39 (3H, m), 7.05 (1H, dd, J = 5.3, 1.8 Hz), 4.22-3.73 (2H, m), 3.06-2.64 (4H, m), 2.06-
1.94 (1H, m), 1.91-1.79 (1H, m), 1.75-1.63 (1H, m), 1.53-1.40 (10H, m), 1.39-1.27 (1H, m); 
13C NMR (100 MHz, CDCl3) : 157.29, 154.74, 149.62, 149.19, 139.07, 129.12, 128.76, 
126.96, 119.08, 117.87, 79.56, 48.92 (br), 44.30 (br), 35.18, 34.18 (br), 28.40, 24.24 (br); 








Tert-butyl (R)-3-((2-phenylpyridin-4-yl)thio)pyrrolidine-1-carboxylate (2h) 
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), tert-butyl (R)-3-mercaptopyrrolidine-1-carboxylate (112 mg, 0.5 
mmol, in 1.0 mL of THF), triphenyl(2-phenylpyridin-4-yl) phosphonium 
trifluoromethanesulfonate (1a, 283 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 30% EtOAc in hexanes) afforded the title compound (2h) as 
a clear oil (160 mg, 0.45 mmol, 90% yield). IR max/cm-1 (film): 2976, 2877, 2246, 1685, 
1570, 1535, 1400, 1365, 1163, 1115, 908, 772, 728, 694; 1H NMR (400 MHz, CDCl3) : 
8.50 (1H, br s), 7.93 (2H, d, J = 7.3 Hz), 7.53 (1H, s), 7.50-7.36 (3H, m), 7.06 (1H, d, J = 
5.1 Hz), 4.04-3.76 (2H, m), 3.68-3.25 (3H, m), 2.43-2.28 (1H, m), 2.07-1.91 (1H, m), 1.45 
(9H, s); 13C NMR (100 MHz, CDCl3) : 157.67, 154.30, 149.52, 148.39, 139.01, 129.32, 
128.85, 127.07, 119.98, 118.76, 79.87, 51.88, 51.62(rot), 47.75, 44.53(rot), 42.42, 41.71(rot), 










Prepared according to general procedure using sodium hydride (60% dispersion in 
mineral oil, 11 mg, 0.28 mmol), tert-butyl (R)-(3-mercapto-1-morpholino-1- oxopropan-2-
yl)carbamate (80 mg, 0.28 mmol, in 1.0 mL of THF), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (1a, 142 mg, 0.25 mmol) and THF (1.0 mL). Flash 
column chromatography (silica gel: 50% EtOAc in hexanes) afforded the title compound (2i) 
as a clear oil (21 mg, 0.05 mmol, 19% yield). IR max/cm-1 (film): 3062, 2984, 2903, 1784, 
1677, 1523, 1161, 1138, 1079, 984, 847, 776, 687; 1H NMR (400 MHz, CDCl3) : 8.50  (1H, 
d, J = 5.1  Hz), 8.08 (2H, d, J = 7.4  Hz), 7.76  (1H, m), 7.56-7.37 (3H, m), 7.15 (1H, d, J = 
5.1  Hz), 4.90 (1H, m), 3.81-3.16  (10H, m), 1.43 (9H, s); 13C NMR (100 MHz, CDCl3) : 
169.01, 157.89, 155.04, 149.55, 148.40, 138.91, 129.45, 128.87, 127.28, 119.22, 117.11, 80.71, 
66.70, 48.66, 46.69, 33.26, 28.46; m/z HRMS (DART) found [M+H]+ 444.1944, 







4-(benzylthio)-2-chloropyridine (2k)   
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), benzyl thiol (68 L, 0.58 mmol), (2- chloropyridin-4-
yl)triphenylphosphonium trifluormethane sulfonate (262 mg, 0.50 mmol) and THF (2.0 mL). 
Flash column chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound 
(2k) as a white solid (106 mg, 0.45 mmol, 90% yield). mp 58-62 oC; IR max/cm-1 (film): 
3068, 3028, 3007, 2920, 1568, 1522, 1456, 1370, 1150, 1078, 821, 794, 777, 713, 685; 1H NMR 
(400 MHz, CDCl3) : 815  (1H, d, J = 5.3 Hz), 7.42-7.27  (4H, m), 7.15  (1H, d, J = 1.5 Hz), 
7.02 (1H, dd, J = 5.4, 1.7 Hz), 4.21 (2H, s); 13C NMR (100 MHz, CDCl3) : 152.33, 151.65, 
148.79, 134.85, 128.90, 128.70, 127.92, 120.24, 119.43, 35.78; m/z HRMS (DART) found 
[M+H]+ 236.0307, C12H11ClNS+ requires 236.0295 
4-(benzylthio)-2-bromopyridine (2l) 
 
 Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), benzyl thiol (68 L, 0.58 mmol), (2-bromopyridin-4-
yl)triphenylphosphonium trifluormethanesulfonate (284 mg, 0.50 mmol) and THF (2.0 mL). 
Flash column chromatography (silica gel, dry load: 5% EtOAc in hexanes) afforded the title 
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compound (2l) as a white solid (114 mg, 0.41 mmol, 81% yield). mp 59-63 oC; IR max/cm-1 
(film): 3063, 2918, 1560, 1515, 1453, 1365, 1245, 1069, 981, 821, 765, 712, 678; 1H NMR 
(400 MHz, CDCl3) : 8.12 (1H, dd, J = 5.4, 0.5 Hz), 7.41-7.27 (5H, m), 7.05 (1H, dd, J 5.4, 
1.7 Hz), 4.21 (2H, s); 13C NMR (100 MHz, CDCl3) : 152.12, 149.15, 142.29, 134.81, 
128.90, 128.72, 127.93, 123.90, 119.79, 35.78; m/z HRMS (DART) found [M+H]+ 
278.9718, C12H11BrNS+ requires 279.9790. 
4-(benzylthio)-2-fluoropyridine (2j)    
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), (2-fluoropyridin-4-
yl)triphenylphosphonium trifluormethanesulfonate (284 mg, 0.50 mmol) and THF (2.0 mL). 
Flash column chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound 
(2j) as a white amorphous solid (62 mg, 0.28 mmol, 57% yield). IR max/cm-1 (film): 3063, 
3027, 2918, 1560, 1515, 1453, 1365, 1244, 1069, 821, 765, 712, 677; 1H NMR (400 MHz, 
CDCl3) d: 7.99 (1H, d, J = 5.4 Hz), 7.42-7.27 (5H, m), 7.05 (1H, dt, J = 5.5, 1.7 Hz), 4.23 (2H, 
s); 13C NMR (100 MHz, CDCl3) d: 163.98 (d, J = 237.49 Hz), 154.65, (d, J = 8.6 Hz), 146.97, 
(d, J = 16.2 Hz), 135.01, 128.99, 128.77, 127.99, 118.63, (d, J = 3.7 Hz), 105.61 (d, J = 40.4 
Hz), 35.910;  19F NMR (365 MHz, CDCl3), 68.26; m/z HRMS (DART) found [M+H]+ 




4-(benzylthio)-2,2’-bipyridine (2p)   
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral oil, 
22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), [2,2’- bipyridin]-4-
yltriphenylphosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (2.0 mL). 
Flash column chromatography (silica gel, dry load: 10% EtOAc in hexanes) afforded the title 
compound (2p) as a white solid (85 mg, 0.31 mmol, 61% yield). mp 99-103 oC; IR max/cm—
1 (film): 3064, 2918, 1574, 1561, 1534, 1446, 1378, 987, 789, 716, 705, 697; 1H NMR (400 
MHz, CDCl3) :  8.68 (1H, d, J = 5.3 Hz), 8.45 (1H, d, J = 5.3 Hz), 8.39-8.34 (2H, m), 7.81 
(1H, tdd, J = 7.7, 1.6, 1.2 Hz), 7.44 (2H, d, J = 7.6 Hz), 7.37-7.27 (4H, m), 7.13 (1H, dd, J = 
5.2, 1.7 Hz), 4.32 (2H, s); 13C NMR (100 MHz, CDCl3) : 155.77, 155.71, 150.13, 149.11, 
148.64, 136.90, 135.65, 128.89, 128.74, 127.63, 123.86, 121.26,  120.63,  117.92,  35.77; m/z 
HRMS (DART) found [M+H]+ 279.0958, C15H17N2S+ requires 279.0. 
4-(benzylthio)-5,6,7,8-tetrahydroquinoline (2o)  
 
Prepared according to general procedure using sodium hydride (60% dispersion in 
mineral oil, 22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), triphenyl(5,6,7,8-
tetrahydroquinolin-4-yl)phosphonium trifluoromethanesulfonate (272 mg, 0.50 mmol) 
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and THF (2.0 mL). Flash column chromatography (basic alumina: 10% EtOAc in 
hexanes) afforded the title compound (2o) as a white solid (96 mg, 0.38 mmol, 75% yield). 
mp 126-132 oC; IR max/cm-1 (film): 3028, 2934, 2861, 1560, 1435, 711; 1H NMR (400 
MHz, CDCl3) : 8.19 (1H, d, J = 5.3 Hz), 7.44-7.23 (5H, m), 6.92 (1H, d, J = 5.3 Hz), 
4.17 (2H, s), 2.89 (2H, t, J =  6.0 Hz), 2.61 (2H, t, J =  6.0 Hz), 1.90-1.77 (4H, m); 13C 
NMR (100 MHz, CDCl3) : 156.26, 148.38, 146.08, 135.58, 128.84, 128.80, 128.75, 
127.63, 116.18, 35.57, 32.91, 25.92, 22.68, 22.54; m/z HRMS (DART) found [M+H]+ 
256.1161, C16H18NS+ requires 256.1154. 
4-(benzylthio)-3-phenylpyridine (2n) 
 
Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 22 mg, 0.55 mmol), benzyl thiol (65 mL, 0.55 mmol), triphenyl(3-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (2.0 mL). Flash 
column chromatography (basic alumina: 15% EtOAc in hexanes) afforded the title compound 
(2n) as a white powder (120 mg, 0.44 mmol, 87% yield). mp 93-97 oC; IR max/cm-1 (film): 
3024, 2920, 2645, 1563, 1453, 1390, 764, 699; 1H NMR (400 MHz, CDCl3) : 8.38 (1H, 
d, J = 5.4 Hz), 8.29 (1H, s), 7.49-7.19 (11H, m), 4.10 (2H, s); 13C NMR (100 MHz, 
CDCl3) : 149.18, 148.29, 147.78, 136.63, 135.42, 135.23, 129.32, 128.85, 128.73, 
128.47, 128.29, 127.67, 119.11, 36.21; m/z HRMS (DART) found [M+H]+ 278.1000, 




4-(benzylthio)-5-(3-fluorophenyl)nicotinonitrile (2q)  
 
Prepared according to general procedure using sodium hydride (60% dispersion in 
mineral oil, 22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), (3-cyano-5-(3-
fluorophenyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (304 mg, 
0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 15% EtOAc in 
hexanes) afforded the title compound (2q) as a yellow oil (149 mg, 0.47 mmol, 93% 
yield). IR nmax/cm-1 (film): 3063, 3030, 2230, 1613, 1584, 1545, 1398, 1204, 908, 733, 
696; 1H NMR (400 MHz, CDCl3) : 8.76 (1H, s), 8.53, (1H, s), 7.47-7.39 (1H, m), 7.24-
7.12 (4H, m), 7.06-6.67 (3H, m), 6.92 (1H, d, J = 9.3 Hz), 4.10 (2H, s); 13C NMR (100 
MHz, CDCl3) : 162.45 (d, J = 246.5 Hz), 152.81, 147.28,  140.05, 137.62  (d, J = 7.9  Hz), 
135.62, 130.30  (d, J = 8.3 Hz), 128.94, 128.71, 127.92, 125.40 (d, J = 3.0 Hz), 116.67 (d, 
J = 22.4 Hz), 115.96 (d, J  =  20.9 Hz), 115.06, 39.47; m/z HRMS (DART) found [M+H]+ 










Prepared according to general procedure using sodium hydride (60% dispersion in 
mineral oil, 22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), (5-(4-
methoxyphenyl)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate (298 
mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc 
in hexanes) afforded the title compound (2r) as a yellow oil (136 mg, 0.44 mmol, 88% 
yield). IR max/cm-1 (film): 3028, 2932, 2835, 1610, 1558, 1522, 1381, 1248, 1118, 1033, 
831, 765, 700; 1H NMR (400 MHz, CDCl3) : 8.91 (1H, s), 8.24 (1H, s). 7.38-7.30 (4H, 
m), 7.29-7.18 (3H, m), 6.97-6.92 (2H, m), 4.41 (2H, s), 3.82 (3H, s); 13C NMR (100 MHz, 
CDCl3) : 167.97, 160.10, 156.26, 153.64, 137.00, 132.82, 130.25, 129.25, 128.53, 127.31, 




Prepared according to general procedure using sodium hydride (60% dispersion in mineral oil, 
22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), triphenyl(quinoxalin-2-yl)phosphonium 
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trifluoromethanesulfonate (270 mg, 0.50 mmol) and THF (2.0 mL). Flash column 
chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound (2s) as an 
amorphous tan solid (115 mg, 0.46 mmol, 91% yield). IR max/cm-1 (film): 3060, 3028, 1539, 
1494, 1247, 1150, 1082, 961, 757, 697; 1H NMR (400 MHz, CDCl3) : 8.56 (1H, s), 8.01-7.92 
(2H, m), 7.69 (1H, t, J = 7.4 Hz), 7.61 (1H, t, J = 7.3 Hz), 7.46 (2H, d, J = 7.4 Hz), 7.33-7.18 
(3H, m), 4.57 (2H, s); 13C NMR (100 MHz, CDCl3) : 155.62, 144.53, 142.63, 139.98, 137.33, 
130.19, 129.25, 129.18, 128.57, 128.09, 127.80, 127.39, 33.68; m/z HRMS (DART) found 




Prepared according to general procedure using sodium hydride (60% dispersion in mineral 
oil, 11 mg, 0.28 mmol), benzyl thiol (33 L, 0.28 mmol), (5-chloro-6’-methyl-3-(4-
(methylsulfonyl)phenyl)-[2,3]bipyridine]-4’-yl)triphenylphosphonium 
trifluoromethanesulfonate (192 mg, 0.25 mmol) and THF (1.0 mL). Flash column 
chromatography (basic alumina: 30% EtOAc in hexanes) afforded the title compound (2t) 
as a white amorphous solid (78 mg, 0.16 mmol, 65% yield). IR max/cm-1 (film): 3061, 
1708, 1570, 1544, 1481.1301, 1252, 1140, 1028, 911, 882, 690, 640; 1H NMR (400 MHz, 
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CDCl3) : 8.68 (1H, d, J = 2.2 Hz), 7.94, (1H, s), 7.81-7.72 (3H, m), 7.34-7.21 (7H, m), 
7.01 (1H, s), 4.08 (2H, s), 3.03 (3H, s), 2.47 (3H, s); 13C NMR (100 MHz, CDCl3) : 158.25, 
151.80, 149.17, 148.51, 148.24, 143.14, 140.13, 137.60, 136.84, 135.28, 131.89, 130.11, 
129.93, 128.95, 128.89, 127.93, 127.62, 119.12, 44.56, 36.24, 24.57; m/z HRMS 




Prepared according to general procedure using sodium hydride (60% dispersion in 
mineral oil, 22 mg, 0.55 mmol), benzyl thiol (65 L, 0.55 mmol), (8-chloro-11-(1-
(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-
b]pyridin-4-yl)triphenylphosphoniun trifluoromethanesulfonate (397 mg, 0.50 mmol) 
and THF (2.0 mL). Flash column chromatography (basic alumina, dry load, gradient 
elution: 20% EtOAc in hexanes to 30% EtOAc in hexanes) afforded the title compound 
(2u) as a white solid (129 mg, 0.36 mmol, 51% yield). mp 200-203 oC; IR max/cm-1 (film): 
2989, 2901, 1694, 1548, 1431, 1216, 1108, 1001, 764, 712, 697; 1H NMR (400 MHz, 
CDCl3) : 8.23 (1H,  d, J = 5.3 Hz), 7.40-7.24  (5H,  m),  7.16-7.05  (3H, m), 6.99 (1H, 
d, J = 5.3 Hz), 4.18-4.08 (4H, m), 3.88-3.68 (2H, m), 3.42-3.31 (1H, m), 3.18-3.04 (3H, 
m), 2.92-2.71 (2H, m), 2.52-2.39 (1H, m), 2.38-2.23 (3H, m), 1.24 (3H, t, J = 7.1 Hz); 
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13C NMR (100 MHz, CDCl3) : 156.28, 155.61, 149.07, 146.31, 139.75, 137.95, 137.67, 
135.37, 134.25, 133.07, 130.35, 129.87, 128.95, 128.94, 128.88, 127.91, 126.33, 117.96, 
61.45, 44.88, 36.28, 30.97, 30.75, 28.79, 14.83; m/z HRMS (DART) found [M+H]+ 







Prepared according to general procedure using sodium hydride (60% dispersion in 
mineral oil, 22 mg, 0.55 mmol), benzyl thiol (65 mL, 0.55 mmol), (4-((R)-
(benzyloxy)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)quinolin-2-
yl)triphenylphosphonium trifluoromethanesulfonate (397 mg, 0.50 mmol) and THF (2.0 
mL). Flash column chromatography (basic alumina: 30% EtOAc in hexanes) afforded the 
title compound (2v) as a yellow amorphous solid (157 mg, 0.31 mmol, 62% yield). IR max/ 
cm-1 (film): 3063, 3029, 2928, 2863, 1591, 1549, 1452, 1290, 1094, 907, 758, 729, 697; 
1H NMR (400 MHz, CDCl3) d: 8.09-7.95 (2H, m), 7.66 (1H, dd, J = 8.2, 7.1 Hz), 7.55-
7.42 (3H, m), 7.39-7.18 (9H, m), 5.80-5.66 (1H, m), 5.19 (1H, br s), 4.99-4.85 (2H, m), 
4.61 (2H, s), 4.45 (1H, d, J = 11.4 Hz), 4.37 (1H, d, J = 11.4 Hz), 3.44-3.28 (1H, m), 
3.17-3.00 (2H, m), 2.72-2.54 (2H, m), 2.30-2.18 (1H, m), 1.86-1.39 (4H, m); 13C NMR 
(100 MHz, CDCl3) : 158.90, 148.85, 145.88, 142.07, 138.48, 137.89, 129.48, 129.32, 
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129.13, 128.59, 128.55, 127.88, 127.17, 125.47, 124.57, 123.39 (br), 118.05 (br), 114.31, 
81.17 (br), 71.51, 60.67, 57.22, 43.28, 40.18, 34.03, 28.06, 27.85, 22.40 (br); m/z HRMS 






















































































APPENDIX 2: CHAPTER 3 EXPERIMENTAL 
General Information 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded at ambient temperature on either a 
Bruker Ultrashield-400 (400 MHz) spectrometer, a Varian 400 MR (400 MHz) spectrometer or an Agilent 
Inova 400 (400 MHz) spectrometer. Chemical shifts (δ) are reported in ppm and quoted to the nearest 0.01 
ppm relative to the residual protons in CDCl3 (7.26 ppm), C6D6 (7.16 ppm), (CD3)2SO (2.50 ppm), CD3OD 
(3.31 ppm) or CD3CN (1.94 ppm) and coupling constants (J) are quoted in Hertz (Hz). Data are reported as 
follows: Chemical shift (number of protons, multiplicity, coupling constants). Coupling constants were 
quoted to the nearest 0.1 Hz and multiplicity reported according to the following convention: s = singlet, d 
= doublet, t = triplet, q = quartet, qn = quintet, sext = sextet, sp = septet, m = multiplet, br = broad. Where 
coincident coupling constants have been observed, the apparent (app) multiplicity of the proton resonance 
has been reported. Carbon nuclear magnetic resonance (13C NMR) spectra were recorded at ambient 
temperature on either a Bruker Ultrashield-400 (400 MHz) spectrometer, a Varian 400 MR spectrometer 
(100 MHz) or an Agilent Inova 400 (100 MHz) spectrometer. Chemical shift (δ) was measured in ppm and 
quoted to the nearest 0.1 ppm relative to the residual solvent peaks in CDCl3 (77.0 ppm) or (CD3)2SO (39.5 
ppm). DEPT135, NOE experiments and 2-dimensional experiments (COSY, HMBC and HSQC) were used 
to support assignments where appropriate. 
Low-resolution mass spectra (LRMS) were measured on an Agilent 6310 Quadrupole Mass Spectrometer. 
Infared (IR) spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer as either solids or neat films, 
either through direct application or deposited in CHCl3, with absorptions reported in wavenumbers (cm-1). 
Analytical thin layer chromatography (TLC) was performed using pre-coated Merck glass backed silica gel 
plates (Silicagel 60 F254). Flash column chromatography was undertaken on Fluka or Material Harvest 
silica gel (230–400 mesh) under a positive pressure of air. Visualization was achieved using ultraviolet light 
(254 nm) and chemical staining with basic potassium permanganate solution as appropriate.  
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Tetrahydrofuran (THF), toluene, hexane, diethyl ether and dichloromethane were dried and distilled using 
standard methods.1 Ethyl acetate, Dimethoxyethane (DME), 1,4-dioxane, N,N-Dimethylformamide 
(DMF), chloroform, and acetone were purchased anhydrous from Sigma Aldrich chemical company. All 
reagents were purchased at the highest commercial quality and used without further purification. Reactions 
were carried out under an atmosphere of nitrogen unless otherwise stated. All reactions were monitored by 
TLC, 1H NMR spectra taken from reaction samples, gas chromatography (GC) and gas chromatography-
mass spectrometry (GCMS) using an Agilent 5977A fitted with an Agilent J&W HP-5ms Ultra Inert 
Column (30 m, 0.25 mm, 0.25 µm film) for MS analysis and an Agilent J&W VF-5ms column (10 m, 0.15 
mm, 0.15 µm film) for FID analysis or liquid chromatography mass spectrometry (LCMS) using an Agilent 
6310 Quadrupole Mass Spectrometer. Melting points (mp) were recorded using a Büchi B-450 melting 
point apparatus and are reported uncorrected. 
PPh3 (99%) was purchased from Oakwood Chemical and is most effective when crushed to a powder before 
use. Tf2O (99%) was purchased from Oakwood Chemical and used without further purification but was 
routinely stored in a –20 ºC fridge. NEt3 and DBU were distilled before use. NaH (60% in mineral oil) was 
purchased from Sigma Aldrich and was typically distributed into vials and stored in a desiccator. KH 
(36.3% in Paraffin) was purchased from Sigma Aldrich and was kept in a Glovebox. n-BuLi (1.6M in 
Hexanes) was purchased from Sigma Aldrich and routinely stored in a -20 ºC fridge. 15-Crown-5 was 
purchased from Oakwood Chemical Company and distilled before use and stored in a -20 ºC fridge. 18-







Preparation of Heterocyclic Phosphonium Salt and Aromatic Heteronucleophile Precursors  
4-(Thiophen-3-yl)-7-(trifluoromethyl)quinoline 
 
An oven dried 100 mL round bottom flask under N2 was charged with 4-chloro-7-
(trifluoromethyl)quinoline (973 mg, 4.20 mmol), thiophen-3-ylboronic acid (699 mg, 5.46 mmol), 
Pd(PPh3)4 (97 mg, 0.08 mmol), K2CO3 (1.74 g, 12.6 mmol), 12 mL of H2O and 36 mL of 1,4-dioxane. After 
12 hours of stirring the reaction mixture under reflux was quenched with H2O (20 mL), organic layer 
separated, and aqueous layer extracted with CH2Cl2 (3 x 50 mL). The combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. The crude material was purified by flash chromatography 
(silica gel: 16% EtOAc in hexanes) to provide the title compound as brown solid (1.147 g, 4.12 mmol, 98% 
yield). mp 91‒93 °C; IR υmax/cm-1 (film): 3104, 3064, 1584, 1566, 1506, 1459, 1373, 1325, 1290, 1244, 
1219, 1207, 1191, 1156, 1059, 902, 884, 853, 833, 815, 794, 784, 767, 740; 1H NMR (400 MHz, CDCl3) 
δ: 9.01 (1H, d, J = 4.4 Hz), 8.47 (1H, s), 8.21 (1H, d, J = 8.8 Hz), 7.70 (1H, dd, J = 1.2, 8.8 Hz), 7.56‒7.54 
(2H, m), 7.50 (1H, d, J = 4.4 Hz), 7.34 (1H, dd, J = 1.4, 4.5 Hz); 13C NMR (100 MHz, CDCl3) δ: 151.3, 
147.8, 143.3, 137.6, 131.1 (q, J = 32.6 Hz), 128.6, 128.3, 127.7 (q, J = 4.3 Hz), 127.1, 126.8, 125.4, 123.9 
(q, J = 271.1 Hz), 122.6, 122.2 (q, J = 3.1 Hz); 19F NMR (365 MHz, CDCl3) δ: -62.76; m/z LRMS (ESI + 








An oven dried 100 mL round bottom flask was charged with sodium hydride (60% dispersion in mineral 
oil, 1.5 equiv.). The flask was subjected to three cycles of vacuum/nitrogen backfill before addition of THF 
(14 mL). The mixture was cooled to 0 °C and a mixture of (3-phenylisoxazol-5-yl)methanol (1.31 g, 7.50 
mmol) in THF (7 mL) was added dropwise over 5 minutes, then allowed to stir for 30 mins at 0 °C. A 
solution of 2-chloropyrimidine (568 mg, 5 mmol) in THF (7 mL) was then added dropwise to the reaction 
mixture over 5 minutes. The reaction stirred at 0 °C for 5 minutes then was warmed to room temperature 
and allowed to stir for 14 hours. The mixture was quenched with water (25 mL) and diluted with CH2Cl2 
(25 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 25 mL). 
The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. 
The crude material was purified by flash chromatography (silica gel: 5% EtOAc in CH2Cl2) to provide the 
title compound as a white solid (993 mg, 3.92 mmol, 78% yield). mp 98-105 ºC; IR max/cm-1 (film): 3129, 
3088, 3052, 2986, 1948, 2249, 2162, 1965, 1815, 1607, 1578, 1567, 1471, 1401, 1375, 1323, 1290, 1044, 
688; 1H NMR (400 MHz, CDCl3) : 8.57 (2H, d, J = 4.8 Hz), 7.83-7.76 (2H, m), 7.48-7.42 (3H, m), 7.02 
(1H, t, J = 4.8 Hz), 6.70 (1H, s), 5.59 (2H, s); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + APCI) 







An oven-dried 200 mL round bottom flask was charged with 4-quinolinecarboxaldehyde (2.36 g, 15.0 
mmol), cis-2,6,-dimethylmorpholine (2.03 mL, 16.5 mmol), and sodium triacetoxyhydroborate (6.36 g, 
30.0 mmol). The flask was subjected to three cycles of vacuum/nitrogen backfill. CH2Cl2 (75 mL) was 
added to the reaction flask along with glacial AcOH (1.73 mL). After 1 hour stirring at room temperature, 
the reaction was quenched with a saturated aqeuous solution of NH4Cl (30 mL), diluted with CH2Cl2, and 
the organic layer was separated. The aqueous layer was basified with a saturated aqueous solution of 
NaHCO3 and extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were dried (MgSO4), 
filtered and concentrated in vacuo. The crude material was purified by flash chromatography (silica gel: 
50% EtOAc in hexanes) to provide the title compound as a yellow oil (2.98 g, 11.6 mmol, 77% yield). IR 
max/cm -1 (film): 3035, 2971, 2868, 2813, 2774, 980, 815, 662, 645, 591; 1H NMR (400 MHz, CDCl3) δ: 
8.84 (1H, d, J = 4.3 Hz), 8.23 (1H, d, J = 8.4 Hz), 8.11 (1H, d, J = 8.4 Hz), 7.70 (1H, m), 7.54 (1H, m), 
7.40 (1H, d, J = 4.3 Hz), 3.87 (2H, s), 3.69 (2H, m), 2.72 (2H, d, J = 10.4 Hz), 1.87 (2H, t, J = 10.7 Hz), 
1.13 (6H, d, J = 6.3 Hz); 13C NMR (100 MHz, CDCl3) δ: 150.0, 148.3, 143.6, 129.9, 129.1, 127.6, 126.3, 
124.2, 121.4, 71.7 (2C), 59.6, 19.0; m/z LRMS (ESI+ APCI) found [M+H]+ 257.2, C16H20N2O+ 








An oven dried 200 mL round bottom flask was charged with 4-aminophenol (546 mg, 5.00 mmol). The 
flask was subjected to three cycles of vacuum/nitrogen backfill before addition of CH2Cl2 (25 mL). A 0.2 
M solution of 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene in THF (25 mL) was added dropwise to 
the reaction flask and stirred at room temperature for 16 hrs. The reaction mixture was then filtered and 
rinsed with CH2Cl2 and H2O. The material was then further purified by flash chromatography (silica gel: 
35% EtOAc in Toluene) to provide the title compound (3bs) as a white solid (1.11 g, 3.36 mmol, 84% 
yield). mp 185-195 ºC; IR max/cm-1 (film): 3293, 3109, 2359, 1896, 1672, 1623, 1557, 1480, 1326, 1261, 
1180, 1145, 1124, 1031, 831; 1H NMR (400 MHz, (CD3)2SO) : 9.12 (1H, s), 9.03 (1H, s), 8.48 (1H, s), 
8.10 (1H, d, J = 1.6 Hz), 7.64-7.56 (2H, m), 7.23 (2H, d, J = 8.6 Hz), 6.70 (2H, d, J = 8.8 Hz); 13C NMR 
(100 MHz, (CD3)2SO) q, J = 30.7 Hz), 122.9 (q, J = 273.4 Hz), 
122.8 (q, J = 4.1 Hz), 121.8, 121.0, 116.5 (q, J = 5.8 Hz), 115.2; 19F NMR (365 MHz, (CD3)2SO) δ: -61.46; 
m/z LRMS (ESI + APCI) found [M + H]+ 331.1, C14H11ClF3N2O2+ requires  331.0. 
 4. Preparation of Heterocyclic Phosphonium Salts 
General Procedure A: 
An oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) equipped with a 
stir bar was charged with the heterocycle (1.0 equiv) and placed under a nitrogen atmosphere. CH2Cl2 (0.1 
M) was added, the reaction vessel cooled to –78 ºC and Tf2O (1.0 equiv) was added dropwise over 5 
minutes. The reaction was stirred for 30 minutes before PPh3 (1.1 equiv) was added in one portion. The 
reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and was stirred for a further 30 
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minutes at –78 ºC. The stated organic base (NEt3 or DBU, 1.0 equiv) was added dropwise via syringe, the 
cooling bath was removed, and the reaction was allowed to warm to room temperature while stirring 
(approximately 15-30 minutes). The reaction mixture was quenched with H2O (approximately the same 
volume as CH2Cl2) and the mixture was transferred to a separatory funnel. The mixture was diluted CH2Cl2 
and the resulting organic layer was washed three times with H2O. The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo to approximately 2-10 mL (depending on the scale of the reaction). An 
excess of chilled Et2O (0 ºC) was added to the concentrated solution that was then placed in a –20 ºC 
refrigerator for approximately 1 hour. The resulting suspension was filtered on a frit, the solid washed with 
chilled Et2O (0 ºC) and dried in vacuo to provide the pure phosphonium salt. 
Notes. 
1) PPh3 was crushed into a powder prior to use. 
2) Certain substrates require longer periods for the precipitation step and specific cases are indicated 
below.  
3) In a small number of cases, residual CH2Cl2 can become trapped in the phosphonium salt products. 
In these cases, heating the salts under vacuum (50-100 ºC) removed the solvent. 
4) In order to evaluate regioselectivity from the crude reaction mixtures, a duplicate reaction was 
performed, and aliquots taken after addition of the organic base and warming to room temperature. 
These aliquots were concentrated in vacuo and analyzed by 1H and 31P NMR. 
General Procedure B: 
In oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) equipped with a stir 
bar was charged with the heterocycle (1.0 equiv) and PPh3 (1.0 equiv) and placed under a nitrogen 
atmosphere. CH2Cl2 (0.1 M) was added, the reaction vessel cooled to –78 ºC and Tf2O (1.0 equiv) was 
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added dropwise over 5 minutes. The reaction was stirred1 for 1 hour before DBU (1.0 equiv) was added 
dropwise via syringe, the cooling bath removed, and the reaction warmed to room temperature while stirring 
(approximately 15-30 minutes). The reaction mixture was quenched with H2O (approximately the same 
volume as CH2Cl2) and the mixture was transferred to a separatory funnel. The mixture was diluted CH2Cl2 
and the resulting organic layer was washed three times with H2O. The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo to approximately 2-10 mL (depending on the scale of the reaction). An 
excess of chilled Et2O (0 ºC) was added to the concentrated solution that was then placed in a –20 ºC 
refrigerator for approximately 1 hour. The resulting suspension was filtered on a frit, the solid washed with 
chilled Et2O (0 ºC) and dried in vacuo to provide the pure phosphonium salt. 
Notes. 
1) PPh3 was crushed into a powder prior to use. 
2) Certain substrates require longer periods for the precipitation step and specific cases are indicated 
below.  
3) In a small number of cases, residual CH2Cl2 can become trapped in the phosphonium salt products. 
In these cases, heating the salts under vacuum (50-100 ºC) removed the solvent. 
4) In order to evaluate regioselectivity from the crude reaction mixtures, a duplicate reaction was 
performed, and aliquots taken after addition of the organic base and warming to room temperature. 




                                                          
1 The reaction vessel was placed directly on the middle of the stir plate and the mixture stirred at 
1400-2000 rpms for the duration of the reaction. 
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Triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (1a) 
 
Prepared according to our previous report.2 1H NMR (400 MHz, CDCl3) : 9.01 (1H, app t, J = 5.1 Hz), 
7.93-7.54 (18H, m), 7.50 (1H, ddd, J = 17.8, 5.1, 1.1 Hz), 7.42-7.36 (3H, m); 13C NMR (100 MHz, CDCl3) 
:159.1 (d, J = 9.9 Hz), 151.6 (d, J = 10.7 Hz), 136.7 (d, J = 1.5 Hz), 136.1 (d, J = 3.2 Hz), 134.3 (d, J = 
9.8 Hz), 130.9 (d, J = 13.0 Hz), 130.4, 129.23 (d, J = 84.1 Hz), 129.0, 127.0, 125.3 (d, J = 7.8 Hz), 123.1, 
(d, J = 8.4 Hz), 120.7 (q, J = 321.1 Hz), 115.5 (d, J = 89.1 Hz). The spectroscopic data is in agreement with 
our previous synthesis.2 
Triphenyl(3-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate 
 
Prepared according to our previous report.2 1H NMR (400 MHz, CDCl3) : 8.95 (1H, app t, J = 4.7 Hz), 
8.74 (1H, d, J = 6.8 Hz), 7.85-7.73 (3H, m), 7.73-7.40 (13H, m), 7.11 (1H, t, J = 7.6 Hz), 6.91 (2H, app t, 
J = 7.6 Hz), 6.71 (2H, d, J = 7.5 Hz); 13C NMR (100 MHz, CDCl3) : 153.6 (d, J = 8.0 Hz), 150.0 (d, J = 
10.4 Hz), 141.7 (d, J = 7.3 Hz), 135.4 (d, J = 3.0 Hz), 134.4 (d, J = 4.5 Hz), 134.2 (d, J = 10.3 Hz), 130.6 
(d, J = 13.0 Hz), 129.2, 128.9, 128.3, 128.2, 126.4 (d, J = 83.4 Hz), 120.8 (q, J = 321.2 Hz), 116.9 (d, J = 
89.2 Hz). The spectroscopic data is in agreement with our previous synthesis.2 
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Triphenyl(5,6,7,8-tetrahydroquinolin-4-yl)phosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.2 1H NMR (400 MHz, DMSO-d6) : 8.74 (1H, app t, J = 5.1 Hz), 
8.07-7.93 (3H, m), 7.92-7.71 (12H, m), 6.94 (1H, dd, J = 15.3, 5.1 Hz), 3.12-2.97 (2H, m), 2.21-2.04 (2H, 
m), 1.84-1.71(2H, m), 1.60-1.44 (2H, m); 13C NMR (100 MHz, CDCl3) : 160.3 (d, J = 8.4 Hz), 148.2 (d, 
J = 11.4 Hz), 135.5 (d, J = 7.6 Hz), 135.3 (d, J = 3.1 Hz), 134.1 (d, J = 10.7 Hz), 130.5 (d, J = 13.0 Hz), 
126.2 (d, J = 9.9 Hz), 125.5 (d, J = 82.4 Hz), 120.4 (q, J = 322.0 Hz), 116.3 (d, J = 87.7 Hz), 32.0 (d, J = 
2.3 Hz), 29.7 (d, J = 5.3 Hz), 21.0, 20.5. The spectroscopic data is in agreement with our previous synthesis.2 
(3-Cyano-5-(thiophen-3-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate  
        
Major 
11.4:1 Mixture of Regioisomers 
Prepared according to our previous report.3 1H NMR (400 MHz, DMSO-d6) : 9.45 (1H, d, J = 5.0 Hz), 
9.07 (1H, d, J = 5.5 Hz), 7.98-7.84 (9H, m), 7.77-7.67 (6H, m), 7.21-7.16 (1H, m), 7.13 (1H, br s), 6.57 
(1H, d, J = 4.9 Hz); Major isomer, 13C NMR (100 MHz, DMSO-d6) : 157.0 (d, J = 6.9 Hz), 154.7 (d, J = 
5.8 Hz), 140.2 (d, J = 5.5 Hz), 135.3 (d, J = 3.0 Hz), 134.5 (d, J = 10.8 Hz), 130.4 (d, J = 13.3 Hz), 128.5, 
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128.3 (d, J = 84.5 Hz), 128.3, 127.8, 120.7 (q, J = 322.4 Hz), 117.0 (d, J = 88.5 Hz), 113.9 (d, J = 6.0 Hz), 




Prepared according to general procedure B (except the reaction was cooled to ‒50 ºC for the Tf2O addition, 
then cooled to ‒78 ºC for the DBU addition) using 4-(thiophen-3-yl)-7-(trifluoromethyl)quinoline (805 mg, 
2.88 mmol), PPh3 (831 mg, 3.17 mmol), Tf2O (484 μL, 2.88 mmol)  and CH2Cl2 (29 mL). After the 
purification procedure the pure phosphonium salt was isolated as an off-white solid (1.68 g, 2.33 mmol, 
81% yield). mp 234-237 °C; IR υmax/cm-1 (film): 3064, 1739, 1575, 1540, 1501, 1484, 1439, 1421, 1378, 
1335, 1224, 1167, 1140, 1108, 1065, 1030, 997, 918, 835, 797, 785, 748, 728, 701, 689, 663, 631; 1H NMR 
(400 MHz, CDCl3) δ: 8.52 (1H, s), 8.40 (1H, d, J = 8.9 Hz), 7.92‒7.87 (4H, m), 7.82‒7.75 (14H, m), 7.55 
(1H, dd, J = 3.0, 4.7 Hz), 7.34 (1H, J = 4.9 Hz); 13C NMR (100 MHz, CDCl3) δ: 148.6, 148.3, 147.5, 146.5 
(d, J = 10.5 Hz), 146.4, 135.9 (d, J = 2.9 Hz), 135.5 (d, J = 1.5 Hz), 134.7 (d, J = 10.1 Hz), 133.2 (q, J = 
33.2 Hz), 130.7 (d, J = 12.9 Hz), 128.6 (d, J = 2.4 Hz), 128.3, 128.1, 128.0, 127.8, 125.9‒125.6 (m), 123.2 
(q, J = 271.7 Hz), 120.7 (q, J = 319.6 Hz), 116.7 (d, J = 88.0 Hz); 19F NMR (365 MHz, CDCl3) δ: ‒63.08, 
‒78.20; 31P NMR (162 MHz, CDCl3) δ: 15.62; m/z LRMS (ESI + APCI) found [M-OTf]+ 540.2, 







Prepared according to general procedure A using 2-methoxypyridine (52.5 µL, 0.50 mmol), PPh3 (144 mg, 
0.55 mmol), Tf2O (84 µL, 0.50 mmol), DBU (75 µL, 0.50 mmol) and CH2Cl2 (5.0 mL). After the 
purification procedure, the title compound was isolated as a white solid (174 mg, 0.34 mmol, 67% yield). 
mp 149-154 ℃; IR υmax/cm-1 (film): 3063, 2956, 2360, 1980, 1583, 1438, 1380, 1264, 1143, 1107, 1031, 
722, 635; 1H NMR (400 MHz, CDCl3) : 8.57 (1H, t, J = 5.3 Hz), 7.97-7.87 (3H, m), 7.85-7.74 (6H, m), 
7.71-7.59 (6H, m), 7.12 (1H, dd, J = 11.5 Hz, 5.0 Hz), 6.84 (1H, d, J = 15.0 Hz), 4.01 (3H, s); 13C NMR 
(100 MHz, CDCl3) : 164.5 (d, J = 15.7 Hz), 149.8 (d, J = 10.5 Hz), 136.1 (d, J = 2.9 Hz), 134.2 (d, J = 
10.5 Hz), 130.9 (d, J = 13.5 Hz), 130.5 (d, J = 85.2 Hz), 120.7 (q, J = 321.2 Hz), 118.8 (d, J = 8.3 Hz), 
116.2 (d, J = 10.0 Hz), 115.6 (d, J = 89.6 Hz), 54.3; 19F NMR (365 MHz, CDCl3) : -78.17; 31P NMR (162 











Prepared according to our previous report.2 Major isomer, 1H NMR (400 MHz, CDCl3) : 9.44 (1H, s), 8.98 
(1H, d, J = 9.0 Hz), 7.80-7.70 (3H, m), 7.67-7.56 (12H, m), 6.91 (2H, d, J = 8.7 Hz), 6.55 (2H, d, J = 8.7 
Hz), 3.72 (3H, s); Minor isomer, 1H NMR (400 MHz, CDCl3) : 9.23 (2H, s), 7.80-7.70 (3H, m), 7.70 (2H, 
d, J = 8.7 Hz), 7.67-7.56 (12H, m), 7.09 (2H, d, J = 8.6 Hz), 3.88 (3H, s); Major isomer, 13C NMR (100 
MHz, CDCl3) : 161.8 (d, J = 5.3 Hz), 160.5, 157.0 (d, J = 16.8 Hz), 149.7 (d, J = 114.5 Hz), 142.7 (d, J 
= 19.2 Hz), 135.2 (d, J = 3.1 Hz), 134.7 (d, J = 10.2 Hz), 130.6, 130.3 (d, J = 13.1 Hz), 123.6, 120.8 (q, J 
= 321.3 Hz), 117.1 (d, J = 88.6 Hz), 114.4, 55.4. 
(3-Cyanopyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.4 1H NMR (400 MHz, CDCl3) δ: 9.21 (1H, dd, J = 4.2, 4.1), 9.16 
(1H, d, J = 5.5 Hz), 7.95–7.91 (3H, m), 7.83–7.71 (13H, m); 13C NMR (100 MHz, CDCl3) δ: 155.5 (d, J = 
9.2 Hz), 154.9 (d, J = 5.5 Hz), 136.4 (d, J = 3.1 Hz), 134.7 (d, J = 10.7 Hz), 131.0 (d, J = 13.3 Hz), 130.9 
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(d, J = 82.7 Hz), 130.2 (d, J = 7.4 Hz), 120.6 (q, J = 319.6 Hz), 114.4 (d, J = 89.5 Hz), 113.6 (d, J = 5.1 Hz), 
111.8.  
(3-Cyano-5-(3-fluorophenyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.5 1H NMR (400 MHz, CDCl3) : 9.10 (1H, dd, J = 4.9, 1.2 Hz), 
8.83 (1H, dd, J = 5.5, 1.1 Hz), 7.92-7.44 (15H, m), 7.02-6.92 (1H, m), 6.84-6.73 (2H, m), 6.70 (1H, d, J = 
8.9 Hz); 13C NMR (100 MHz, CDCl3) : 162.6 (d, J = 247.8 Hz), 152.8, 147.3, 140.1, 137.6 (d, J = 7.9 
Hz), 135.6, 130.3 (d, J = 8.4 Hz), 129.0, 128.7, 127.9, 125.4 (d, J = 3.1 Hz), 116.7 (d, J, 22.5 Hz), 116.0 
(d, J = 21.0 Hz), 115.1. 
Triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.2 1H NMR (400 MHz, CDCl3) : 9.33 (1H, d, J = 2.8 Hz), 8.02 
(1H, m), 7.92 (3H, m), 7.82–7.69 (13H, m); 13C NMR (100 MHz, CDCl3) : 154.2 (d, J = 19.9 Hz), 147.0 
(d, J = 121.0 Hz), 139.9 (qd, J = 35.8 Hz, 11.3 Hz), 136.0 (d, J = 2.9 Hz), 134.5 (d, J = 10.2 Hz), 130.7 (d, 
J = 13.1 Hz), 126.1 (dq, J = 25.9, 3.6 Hz), 124.4 (m), 121.5 (qd, J = 274.1, 3.0 Hz), 120.7 (q, J = 320.5 Hz), 
115.9 (d, J = 90.0 Hz). The spectroscopic data is in agreement with our reported synthesis.2 
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(4-Methylquinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.3 1H NMR (400 MHz, CDCl3) : 8.22-8.12 (2H, m), 7.94-7.65 
(17H, m), 7.53, (1H, d, J = 4.6 Hz), 2.81 (3H, s); 13C NMR (100 MHz, CDCl3) : 148.5 (d, J = 10.6 Hz), 
148.5 (d, J = 22.6 Hz), 144.4 (d, J = 117.2 Hz), 135.6 (d, J = 3.1 Hz), 134.6 (d, J = 10.1 Hz), 131.6, 130.6 
(d, J = 1.2 Hz), 130.5 (d, J = 12.9 Hz), 130.4, 128.8, 125.1 (d, J = 26.4 Hz), 124.4 (d, J = 1.3 Hz), 120.8 (q, 
J = 321.2 Hz), 117.3 (d, J = 88.2 Hz), 19.2 (d, J = 1.5 Hz). 
(5-Bromo-2-(methylthio)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate 
 
Prepared according to our previous report.3 1H NMR (400 MHz, CDCl3) : 8.82 (1H, d, J = 7.9 Hz), 7.97-
7.85 (3H, m), 7.83-7.66 (12H, m), 2.15 (3H, s); 13C NMR (100 MHz, CDCl3) : 173.9 (d, J = 17.2 Hz), 
162.0 (d, J = 4.1 Hz), 151.4 (d, J = 118.7 Hz), 136.1 (d, J = 3.1 Hz), 134.8 (d, J = 10.4 Hz), 130.7 (d, J = 







Prepared according to our previous report.6 1H NMR (400 MHz, CDCl3) : 8.99 (1H, s), 8.27-8.22 (2H, m), 
8.09-8.01 (2H, m), 7.93-7.90 (3H, m), 7.79-7.72 (12H, m); 13C NMR (100 MHz, CDCl3) : 145.9 (d, J = 
25.4 Hz), 143.4 (d, J = 2.8 Hz), 142.7 (d, J = 17.3 Hz), 140.8 (d, J = 111.6 Hz), 136.2 (d, J = 3.1 Hz), 135.0, 
134.7 (d, J = 10.5 Hz), 133.1, 130.9 (d, J = 13.0 Hz), 130.2 (d, J = 2.0 Hz), 129.9 (d, J = 2.3 Hz), 120.8 (q, 
J = 319.5 Hz), 116.0 (d, J = 88.1 Hz). 
[2,2'-Bipyridin]-4-yltriphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.2 1H NMR (400 MHz, CDCl3) : 9.06 (1H, app t, J = 5.1 Hz), 
8.65 (1H, d, J = 13.8 Hz), 8.55 (1H, d, J = 4.4 Hz), 8.46 (1H, d, J = 7.9 Hz), 7.96-7.88 (3H, m), 7.87-7.74 
(7H, m), 7.72-7.55 (7H, m), 7.35 (1H, dd, J = 7.7, 4.5 Hz); 13C NMR (100 MHz, CDCl3) : 157.8 (d, J = 
9.9 Hz), 153.4 (d, J = 2.3 Hz), 151.4 (d, J = 10.7 Hz), 149.3, 137.3, 136.2 (d, J = 3.1 Hz), 134.4 (d, J = 9.9 
Hz), 131.0 (d, J = 13.0 Hz), 129.3 (d, J = 83.9 Hz), 126.9 (d, J = 8.4 Hz), 125.1, 123.9 (d, J = 9.2 Hz), 







Prepared according to general procedure B (except the reaction was cooled to -50 ºC for the Tf2O addition, 
then cooled to -78 ºC for the DBU addition) using (2R,6S)-2,6-dimethyl-4-(quinolin-4-
ylmethyl)morpholine (558 mg, 2.18 mmol), PPh3 (629.3 mg, 2.39 mmol), Tf2O (340 µL, 2.18 mmol), DBU 
(325 µL, 2.18 mmol) and CH2Cl2 (22 mL). After the purification procedure, the title compound was isolated 
as a white solid (994 mg, 1.49 mmol, 68% yield). mp 188-195 ℃; IR max/cm-1 (film): 3072, 2972, 2937, 
2825, 1576, 1439, 1267, 1144, 1110, 1027, 727, 633; 1H NMR (400 MHz, CDCl3) : 8.26 (2H, dd, J = 8.4, 
16.5 Hz), 7.96-7.70 (18H, m), 4.02 (2H, s), 3.50-3.38 (2H, m), 2.60 (2H, d, J = 10.7 Hz), 1.92 (2H, t, J = 
10.5 Hz), 1.10 (6H, d, J = 6.2 Hz); 13C NMR (100 MHz, CDCl3) : 149.0 (d, J = 22.2 Hz), 148.2 (d, J = 
10.1 Hz), 144.7 (d, J = 117.6 Hz), 135.7 (d, J = 3.0 Hz), 134.7 (d, J = 10.0 Hz), 131.7, 130.9, 130.6, 130.6 
(d, J = 12.9 Hz), 127.9 (d, J = 3.1 Hz), 124.0, 123.6 (d, J = 27.4 Hz), 120.9 (q, J = 321.1 Hz), 117.4 (d, J = 
88.2 Hz), 71.6, 59.3, 58.1, 18.9 ; 19F NMR (365 MHz, CDCl3) : -78.09; 31P NMR (162 MHz, CDCl3) : 








Prepared according to general procedure A using 6-isopropylnicotinonitrile (438.6 mg, 3.0 mmol), Tf2O 
(500 µL, 3.0 mmol), PPh3 (866 mg, 3.3 mmol), DBU (450 µL, 3.0 mmol) and CH2Cl2 (30 mL). After the 
purification procedure, the title compound was isolated as an off-white solid (1.02 g, 1.83 mmol, 61% 
yield). mp 59-66 ℃; IR max/cm-1 (film): 3063, 2970, 2933, 2873, 2228, 1571, 1481, 1439, 1259, 1147, 
1106, 1029; 1H NMR (400 MHz, CDCl3) : 9.10 (1H, d, J = 5.8 Hz), 7.96-7.90 (3H, m), 7.86-7.73 (12H, 
m), 7.34 (1H, d, J = 15.3 Hz), 3.20 (1H, sp, J = 6.9 Hz), 1.27 (6H, d, J = 6.8 Hz); 13C NMR (100 MHz, 
CDCl3) : 174.5 (d, J = 8.9 Hz), 154.8 (d, J = 6.1 Hz), 136.3 (d, J = 3.0 Hz), 134.6 (d, J = 10.8 Hz), 131.0 
(d, J = 82.5 Hz), 131.0 (d, J = 13.4 Hz), 127.6 (d, J = 7.5 Hz), 120.6 (q, J = 321.2 Hz), 114.4 (d, J = 89.8 
Hz), 113.9 (d, J = 5.2 Hz), 108.9 (d, J = 3.7 Hz), 36.9, 21.5; 19F NMR (365 MHz, CDCl3) : -78.22; 31P 











Prepared according to our previous report.7 Major isomer, 1H NMR (400 MHz, CDCl3) : 9.04 (1H, dd, J 
= 7.6, 5.0 Hz), 8.54-8.35 (2H, m), 8.03-7.57 (17H, m), 7.34-7.11 (1H, m), 4.29 (2H, s); Major isomer, 13C 
NMR (100 MHz, CDCl3)  173.7 (d, J = 17.6 Hz), 160.6 (d, J = 7.4 Hz), 154.6 (d, J = 111.5 Hz), 149.6, 
148.6, 136.2, 136.1 (d, J = 2.9 Hz), 134.6 (d, J = 10.3 Hz), 132.2, 130.7 (d, J = 13.1 Hz), 123.4, 123.1 (d, 




13.4:1:1 Mixture of Regioisomers 
Prepared according to our previous report.3 Major Isomer, 1H NMR (400 MHz, CDCl3) : 9.08 (1H, app t, 
J = 4.7 Hz), 8.79 (1H, d, J = 6.8 Hz), 8.70 (1H, d, J = 4.7 Hz), 8.27 (1H, d, J = 1.7 Hz), 7.87-7.58 (18H, 
m), 7.55 (1H, d, J = 7.8 Hz), 7.39 (1H, dd, J = 7.8, 4.7 Hz); Major Isomer, 13C NMR (100 MHz, CDCl3) : 
105 
 
156.1, 155.3, 153.1 (d, J = 7.3 Hz), 151.3 (d, J = 9.9 Hz), 151.0, 150.6, 148.8, 136.4, 136.2-136.1(m), 135.7 
(d, J = 6.5 Hz), 135.7 (d, J = 2.8 Hz), 134.2 (d, J = 10.3 Hz), 130.7 (d, J = 13.0 Hz), 128.7 (d, J = 9.0 Hz), 
127.5 (d, J = 83.1 Hz), 123.9 (q, J = 33.8 Hz), 123.8, 123.4, 122.2 (q, J = 273.7 Hz), 120.6 (q, J = 321.3 











Prepared according to our previous report.3 1H NMR (400 MHz, CDCl3) : 8.99 (1H, app t, J = 5.1 Hz), 
7.91-7.80 (3H, m), 7.78-7.66 (6H, m), 7.63-7.37 (15H, m), 7.29 (1H, d, J = 13.8 Hz), 5.97 (1H, s); 13C 
NMR (100 MHz, CDCl3) : 164.0 (d, J = 9.8 Hz), 151.6 (d, J = 10.4 Hz), 141.7, 136.1 (d, J = 3.1 Hz), 
134.3 (d, J = 10.5 Hz), 132.9 (d, J = 1.1 Hz), 130.9 (d, J = 13.1 Hz), 130.7 (q, J = 32.2 Hz), 130.0, 129.6 
(d, J = 83.7 Hz), 127.0 (d, J = 8.7 Hz), 125.7-125.4 (2C, m), 124.0 (q, J = 3.8 Hz), 123.8 (q, J = 272.5 Hz), 


















Prepared according to general procedure B (except the reaction was cooled to -50 ºC for the Tf2O addition, 
then cooled to -78 ºC for the DBU addition and EtOAc was used instead of CH2Cl2) using 3-phenyl-5-
((pyrimidin-2-yloxy)methyl)isoxazole (253.3 mg, 3.0 mmol), PPh3 (865.6 mg, 3.3 mmol), Tf2O (0.50 mL, 
3.0 mmol), DBU (0.45 mL, 3.0 mmol) and EtOAc (15 mL). After the purification procedure, the title 
compound was isolated as an off-white solid (798.6 mg, 1.20 mmol, 40% yield). mp 49-55 ℃; IR max/cm-
1 (film): 3500, 3064, 2162, 1980, 1613, 1587, 1547, 1439, 1352, 1259, 1223, 1149, 1109, 1029, 688, 635, 
529; 1H NMR (400 MHz, CDCl3) : 9.10 (1H, t, J = 6.8 Hz), 7.90-7.83 (3H, m), 7.82-7.67 (15H, m), 7.49-
7.43 (3H, m), 6.69 (1H, s), 5.58 (2H, s); 13C NMR (100 MHz, CDCl3) : 166.6, 164.4 (d, J = 19.5 Hz), 
163.8 (d, J = 8.4 Hz), 162.5, 156.0 (d, J = 112.4 Hz), 136.1 (d, J = 3.0 Hz), 134.7 (d, J = 10.4 Hz), 130.7 
(d, J = 13.1 Hz), 130.2, 128.9, 128.4, 126.8, 122.5 (d, J = 20.2 Hz), 120.7 (q, J = 320.2 Hz), 115.1 (d, J = 
89.1 Hz), 102.4, 60.6; 19F NMR (365 MHz, CDCl3) : -78.20; 31P NMR (162 MHz, CDCl3) : 16.36; m/z 






yl)triphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.3 1H NMR (400 MHz, CDCl3`) : 8.90 (1H, t, J = 5.1 Hz), 7.94-
7.86 (3H, m), 7.82-7.73 (6H, m), 7.71-7.59 (7H, m), 7.49 (1H, ddd, J = 12.6, 5.0, 1.1 Hz), 7.34-7.25 (4H, 
m), 5.71 (1H, s), 4.11 (2H, q, J = 7.1 Hz), 3.70-3.60 (1H, m), 3.55-3.42 (2H, m), 3.25-3.12 (2H, m), 1.79-
1.56 (2H, m), 1.54-1.37 (2H, m), 1.25 (3H, t, J = 7.1 Hz); 13C NMR (100 MHz, CDCl3) : 164.4 (d, J = 
9.6 Hz), 155.4, 151.1 (d, J =10.5 Hz), 138.7, 136.2 (d, J = 3.1 Hz), 134.5 (d, J = 10.5 Hz), 134.0, 131.0 (d, 
J = 13.1 Hz), 129.3 (d, J = 84.1 Hz), 128.8, 128.5, 125.9 (d, J = 8.4 Hz), 123.9 (d, J = 9.1 Hz), 120.8 (q, J 











Prepared according to our previous report.4 1H NMR (400 MHz, CDCl3) δ: 9.15 (1H, d, J = 6.8 Hz), 8.84 
(1H, app t, J = 4.6 Hz), 7.91-7.70 (17H, m), 7.54 (1H, dd, J = 7.4, 7.8 Hz), 7.33 (1H, dd, J = 7.6, 7.5 Hz), 
7.20 (1H, dd, J = 5.0, 15.6 Hz), 6.59 (1H, s), 3.26 (2H, s), 2.81 (4H, s), 2.62 (3H, s), 2.16 (4H, s); 13C NMR 
(100 MHz, CDCl3) δ: 159.1, 156.4, 153.5 (d, J = 8.3 Hz), 150.8 (d, J = 10.6 Hz), 148.4, 137.0 (d, J = 5.7 
Hz), 135.7 (d, J = 2.9 Hz), 134.0 (d, J = 10.2 Hz), 131.0 (d, J = 13.0 Hz), 129.3, 129.1 (d, J = 9.8 Hz), 
128.5, 126.7 (d, J = 81.7 Hz), 124.6, 123.2, 121.3, 120.8 (q, J = 319.4 Hz), 117.0 (d, J = 88.9 Hz), 109.2, 




Prepared according to our previous report.2 1H NMR (400 MHz, CDCl3) : 9.09 (1H, s), 8.10-7.72 (17H, 
m), 7.20-7.05 (3H, m), 6.92-6.80 (2H, m), 3.55-3.27 (4H, m), 3.03-2.87 (2H, m), 2.66-2.42 (2H, m), 2.29-
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2.15 (1H, m), 1.87 (1H, d, J = 10.8 Hz); 13C NMR (100 MHz, CDCl3): 144.9 (d, J = 23.5 Hz), 144.2, 
143.5 (d, J = 16.9 Hz), 137.5 (br s), 136.0 (d, J = 2.9 Hz), 134.6 (d, J = 10.9 Hz), 130.7 (d, J = 13.0 Hz), 
129.2-126.2 (3C, m,), 120.7 (br s), 120.7 (q, J = 321.5 Hz), 116.4 (d, J = 88.3 Hz), 61.3, 57.9-56.1 (2C, 














Prepared according to our previous report.6 1H NMR (400 MHz, CDCl3) : 8.54 (1H, d, J = 8.1 Hz), 8.26 
(1H, d, J = 8.6 Hz), 7.94 (1H, t, J = 7.2 Hz), 7.91-7.60 (17H, m), 7.29-7.02 (3H, m), 7.14-7.02 (2H, m), 
5.83-5.45 (2H, m), 5.07-4.89 (2H, m), 4.60 (1H, d, J = 11.4 Hz), 4.33 (1H, d, J = 11.4 Hz), 3.52-3.06 (3H, 
m), 2.84-2.62 (2H, m), 2.49-2.33 (1H, br s), 2.06-1.47 (5H, m); 13C NMR (100 MHz, CDCl3) : 149.2 (d, 
J = 22.1 Hz), 148.5, 145.1, 143.9, 139.5, 136.6, 135.7 (d, J = 3.0 Hz), 134.5 (d, J = 10.0 Hz), 132.0-131.8 
(3C, m), 131.2, 130.4 (d, J = 13.2 Hz), 128.4, 127.9, 127.2, 126.7 (d, J = 3.1 Hz), 126.1, 123.8, 120.6 (q, J 










Prepared according to our previous report.6  1H NMR (400 MHz, CDCl3) : 8.28 (1H, d, J = 7.1 Hz), 8.10 
(2H, d, J = 8.2 Hz), 7.86-7.62 (16H, m), 7.51-7.45 (3H, m), 7.20 (1H, d, J = 16.5 Hz), 3.14 (3H, s), 2.54 
(3H, s); 13C NMR (100 MHz, CDCl3) : 160.8 (d, J = 11.2 Hz), 152.4 (d, J = 7.3 Hz), 147.5 (d, J = 2.2 
Hz), 146.1, 141.5, 141.0, 138.9, 135.6, 134.8 (d, J = 2.9 Hz), 134.1 (d, J = 10.0 Hz), 133.3 (d, J = 3.6 
Hz), 132.1, 130.8 (d, J = 10.2 Hz), 130.0 (d, J = 13.1 Hz), 129.8, 128.5, 128.2 (d, J = 86.2 Hz), 120.8 (q, 











b]pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.2 1H NMR (400 MHz, CDCl3) : 8.73 (1H, app t, J = 5.0 Hz), 
7.97-7.87 (3H, m), 7.86-7.74 (6H, m), 7.73-7.60 (6H, m), 7.16-7.01 (3H, m), 6.71 (1H, s), 4.14 (2H, q, J = 
7.0 Hz), 3.84-3.61 (2H, m), 3.45- 3.20 (3H, m), 2.75 (1H, dt, J = 17.4, 4.7 Hz), 2.58 (1H, dt, J = 14.9, 4.7 
Hz), 2.53-2.30 (3H, m), 2.26-2.09 (1H, m), 1.60-1.43 (1H, m), 1.25 (3H, t, J = 7.2 Hz); 13C NMR (100 
MHz, CDCl3) : 163.6 (d, J = 8.3 Hz), 155.4, 149.1 (d, J = 11.4 Hz), 139.2, 136.8, 136.7 (d, J = 6.8 Hz), 
136.0 (d, J = 3.1 Hz), 134.2 (d, J = 10.7 Hz), 133.9, 133.6, 132.4, 131.6, 131.1 (d, J = 13.0 Hz), 129.9, 
127.2 ( d, J = 10.0 Hz), 127.0 (d, J = 82.2 Hz), 126.4, 120.8 (q, J = 321.3 Hz), 116.4 (d, J = 88.5 Hz), 61.4, 










Prepared according to our previous report.6 1H NMR (400 MHz, CDCl3) : 8.99 (1H, d, J = 7.2 Hz), 8.72 
(1H, app t, J = 4.1 Hz), 7.88-7.59 (15H, m), 7.27 (1H, dd, J = 15.7, 5.2 Hz), 5.55 (1H, s), 5.28 (1H, d, J = 
3.4 Hz), 4.58 (1H, m), 2.33-2.18 (2H, m), 1.99 (3H, s), 1.87-1.30 (10H, m), 1.24-1.01 (5H, m), 0.94 (3H, 
s), 0.79 (1H, td, J = 12.1, 3.7 Hz), 0.57 (1H, td, J = 11.2, 3.9 Hz), –0.22 (1H, m); 13C NMR (100 MHz, 
CDCl3) : 170.4, 150.6 (d, J = 7.5 Hz), 149.0 (d, J = 4.2 Hz), 148.7 (d, J = 10.8 Hz), 139.9, 139.1, 137.4 
(d, J = 6.1 Hz), 135.5 (d, J = 2.9 Hz), 134.2 (d, J = 9.9 Hz), 130.8 (d, J = 13.0 Hz), 130.0 (d, J = 10.5 Hz), 
125.2 (d, J = 83.7 Hz), 121.6, 120.7 (q, J = 321.2 Hz), 118.0 (d, J = 89.6 Hz), 73.5, 55.3, 49.7, 48.7, 
37.9, 36.8, 36.4, 33.5, 32.4, 31.0, 29.7, 27.5, 21.3, 20.3, 19.0, 18.6. The spectroscopic data is in agreement 











Prepared according to our previous report.6 1H NMR (400 MHz, CDCl3) : 8.55 (1H, app t, J = 5.3 Hz), 
7.93-7.87 (3H, m), 7.82-7.74 (6H, m), 7.67-7.59 (6H, m), 7.30-7.23 (2H, m), 7.13 (1H, ddd, J = 11.7, 5.3, 
1.2 Hz), 7.02 (1H, t, J = 7.4 Hz), 6.94-6.77 (7H, m), 5.66 (1H, sext, J = 5.3 Hz), 4.18-4.07 (2H, m), 1.48 
(3H, d, J = 6.4 Hz); 13C NMR (100 MHz, CDCl3) : 163.7 (d, J = 15.9 Hz), 158.1, 154.7, 150.3, 149.8 (d, 
J = 12.1 Hz), 136.1 (d, J = 3.0 Hz), 134.3 (d, J = 10.6 Hz), 130.9 (d, J = 13.0 Hz), 130.8 (d, J = 84.2 Hz), 
129.5, 122.4, 120.8 (q, J = 321.2 Hz), 120.6, 119.1 (d, J = 8.1 Hz), 117.5, 116.6 (d, J = 10.0 Hz), 115.6 










yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate  
 
Prepared according to our previous report.6 Major isomer, 1H NMR (400 MHz, DMSO-d6) : 10.14 (1H, 
s), 9.55 (1H, d, J = 6.7 Hz), 9.09 (1H, app t, J = 4.6 Hz), 8.31 (1H, d, J = 5.1 Hz), 8.00-7.55 (18H, m), 
7.52-7.20 (5H, m), 7.08 (1H, d, J = 8.3 Hz), 6.10 (1H, br), 3.55 (2H, s), 2.70-2.13 (11H, m), 1.74 (3H, s); 
Major isomer, 13C NMR (100 MHz, DMSO-d6) : 165.2, 159.8, 159.7 (d, J = 2.0 Hz), 158.3, 152.7 (d, J = 
11.4 Hz), 151.8 (d, J = 6.8 Hz), 141.1 (br), 137.3, 136.2, 135.8 (d, J = 3.8 Hz), 134.7 (d, J = 2.3 Hz), 133.9 
(d, J = 10.0 Hz), 130.8 (d, J = 10.2 Hz), 130.0, 129.9 (d, J = 13.4 Hz), 128.7, 127.7, 125.6 (d, J = 86.2 
Hz), 125.5, 120.7 (q, J =  322.8 Hz), 119.5 (d, J = 92.3 Hz), 117.0, 117.0, 115.6, 110.3, 60.6, 53.2, 50.1, 


















Prepared according to general procedure A (except the reaction was cooled to -50 ºC for the PPh3 addition) 
using methyl 5-cyclopropylpicolinate (200 mg, 1.12 mmol), Tf2O (190 µL, 1.12 mmol), PPh3 (323 mg, 1.23 
mmol), DBU (170 µL, 1.12 mmol) and CH2Cl2 (11.2 mL). After the purification procedure, the title 
compound (3bu) was isolated as a white solid (276 mg, 0.469 mmol, 42% yield). mp: 173-200 °C; IR 
max/cm-1 (film): 3069, 2953, 1745, 1577, 1439, 1263, 1133, 1030, 721, 635; 1H NMR (400 MHz, CDCl3) 
: 8.47 (1H, d, J = 6.4 Hz), 7.96-7.88 (3H, m), 7.87-7.78 (6H, m), 7.78-7.68 (7H, m), 3.94 (3H, s), 1.44 
(1H, sp, J = 4.7 Hz), 1.08-1.00 (2H, m), 0.92-0.84 (2H, m); 13C NMR (100 MHz, CDCl3) : 163.9 (d, J = 
2.4 Hz), 147.8 (d, J = 6.3 Hz), 146.9 (d, J = 7.6 Hz), 146.4 (d, J = 10.7 Hz), 136.2 (d, J = 3.0 Hz), 134.2 (d, 
J = 10.6 Hz), 131.2 (d, J = 13.2 Hz), 129.0 (d, J = 11.1 Hz), 127.5 (d, J = 84.2 Hz), 120.8 (q, J = 321.1 Hz), 
115.9 (d, J = 89.0 Hz), 53.3, 16.4 (d, J = 6.5 Hz), 13.9; 19F NMR (365 MHz, CDCl3) : -78.17; 31P NMR 







Preparation of Derivatized Azaarenes: 
General Procedure C: 
 
An oven dried 8 mL vial equipped with a septa cap was charged with sodium hydride (60% dispersion in 
mineral oil, 1.5 equiv) and placed under a nitrogen atmosphere. THF (0.5 M) was added and the suspension 
was cooled to 0 ºC while stirring. The phenol or thiophenol (1.5 equiv) was added dropwise over 5 min and 
allowed to stir for 30 min at 0 ºC. The septa cap was briefly removed and the phosphonium salt (1.0 equiv) 
was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and 
was warmed to 60 ºC and stirred for 2 h. The reaction was quenched with H2O, the aqueous layer was 
separated and extracted with CH2Cl2 (3x). The combined organic extracts were washed with a saturated 
aqueous solution of brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by 
flash column chromatography under the stated conditions to provide the heteroaryl ether/thioether. 
Notes. 
1) If the phenol/thiophenol was a solid or viscous liquid, it was added dropwise as a 1.5 M solution to 
an equivalent volume 1.5 M solution of NaH in THF.  
2) Certain substrates required longer reaction times. Specific cases are indicated below.  




4) Certain substrates showed improved yields with the addition of 15-crown-5 right before the salt 
addition. Specific cases are indicated below (Phenol nucleophiles typically require this addition for 
tolerable yields). 
General Procedure D: 
 
An oven dried 8 mL vial equipped with a septa cap was charged with sodium hydride (60% dispersion in 
mineral oil, 1.5 equiv) and placed under a nitrogen atmosphere. THF (0.5 M) was added and the suspension 
was cooled to 0 ºC while stirring. The pyrrole/pyrazole/imidazole (1.5 equiv) was added dropwise over 5 
min and allowed to stir for 30 min at 0 ºC. The septa cap was briefly removed and the phosphonium salt 
(1.0 equiv) was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen 
backfill and was warmed to 60 ºC and stirred for 1 h. The reaction was quenched with H2O, the aqueous 
layer was separated and extracted with CH2Cl2 (3x). The combined organic extracts were washed with a 
saturated aqueous solution of brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography under the stated conditions to provide the coupled azaarene 
product. 
Notes. 
1) If the pyrrole/pyrazole/imidazole was a solid or viscous liquid, it was added dropwise as a 1.5 M 
solution to an equivalent volume 1.5 M solution of NaH in THF.  
2) Certain substrates required longer reaction times. Specific cases are indicated below.  




4) Certain substrates showed improved yields with the addition of 15-crown-5 right before the salt 
addition. Specific cases are indicated below. 
5) Certain substrates showed improved yields when KH was used as the base in place of NaH. Specific 
cases are indicated below. 
General Procedure E: 
 
An oven dried 8 mL vial equipped with a septa cap was charged with the aniline (1.5 equiv) and placed 
under a nitrogen atmosphere. THF (0.25 M) was added and the suspension was cooled to -78 ºC while 
stirring. n-BuLi (1.5 equiv) was added dropwise over 5 min and allowed to stir for 30 min at -78 ºC. The 
reaction was then allowed to warm to room temp before the septa cap was briefly removed and the 
phosphonium salt (1.0 equiv) was added in one portion. The reaction was subjected to three rapid cycles of 
vacuum/nitrogen backfill and stirred for 30 min at room temp. The reaction was quenched with H2O, the 
aqueous layer was separated and extracted with CH2Cl2 (3x). The combined organic extracts were washed 
with a saturated aqueous solution of brine, dried (MgSO4), filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography under the stated conditions to provide the heteroaryl 
ether/thioether. 
Notes. 








Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.5 mmol) and THF (1.0 mL). Flash 
column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 20% EtOAc in hexanes) 
afforded the title compound (3b) as a clear oil (107 mg, 0.39 mmol, 77% yield).  IR max/cm-1 (film): 3066, 
3002, 2947, 2842, 2214, 2042, 1612, 1564, 1499, 1470, 1259, 1208, 1112, 908, 728; 1H NMR (400 MHz, 
CDCl3) : 8.51 (1H, d, J = 5.6 Hz), 7.94-7.88 (2H, m), 7.48-7.37 (3H, m), 7.23 (1H, d, J = 2.3 Hz), 7.10-
7.04 (2H, m), 6.99-6.93 (2H, m), 6.74 (1H, dd, J = 5.7, 2.4 Hz), 3.85 (3H, s); 13C NMR (100 MHz, CDCl3) 
; m/z 
LRMS (ESI + APCI) found [M+H]+ 278.1, C18H16NO2+  requires 278.1. 
4-Phenoxy-2-phenylpyridine (3a) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), phenol (71 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-
120 
 
yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 4% EtOAc & 1% AcOH in hexanes) 
afforded the title compound (3a) as a yellow amorphous solid (87 mg, 0.35 mmol, 70% yield).  IR max/cm-
1 (film): 3062, 2923, 2851, 2215, 1721, 1579, 1562, 1489, 1470, 1305, 1214, 912, 774, 731, 692; 1H NMR 
(400 MHz, CDCl3) : 8.54 (1H, d, J = 5.6 Hz), 7.95-7.88 (2H, m), 7.49-7.38 (5H, m), 7.30-7.24 (2H, m), 
7.17-7.12 (2H, m), 6.78 (1H, dd, J = 5.6, 2.3 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS 
(ESI + APCI) found [M+H]+ 248.1, C17H14NO+  requires 248.1. 
4-(4-Iodophenoxy)-2-phenylpyridine (3d) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-iodophenol (165 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 20% EtOAc in hexanes) 
afforded the title compound (3d) as a pink solid (112 mg, 0.30 mmol, 60% yield). mp: 50-57 °C; IR max/cm-
1 (film): 3084, 3045, 2925, 2503, 2208, 1879, 1594, 1556, 1477, 1408, 1214, 1023, 844, 694; 1H NMR (400 
MHz, CDCl3) : 8.56 (1H, d, J = 5.6 Hz), 7.95-7.89 (2H, m), 7.77-7.71 (2H, m), 7.50-7.38 (3H, m), 7.27 
(1H, d, J = 2.3 Hz), 6.94-6.88 (2H, m), 6.78 (1H, dd, J = 5.6, 2.4 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI 





Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 2-methoxyphenol (82 L, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and DME (1.0 mL). 
Flash column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 20% EtOAc in hexanes) 
afforded the title compound (3c) as a clear oil (79 mg, 0.28 mmol, 57% yield).  IR max/cm-1 (film): 3066, 
3008, 2927, 2839, 2214, 2043, 1580, 1563, 1498, 1470, 1258, 1208, 1112, 907, 728; 1H NMR (400 MHz, 
CDCl3) : 8.50 (1H, d, J = 5.7 Hz), 7.94-7.88 (2H, m), 7.48-7.37 (3H, m), 7.30-7.22 (2H, m), 7.14 (1H, dd, 
J = 7.9, 1.6 Hz), 7.08-6.99 (2H, m), 6.70 (1H, dd, J = 5.7, 2.4 Hz), 3.81 (3H, s); 13C NMR (100 MHz, 
CDCl3) 















Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 3-bromo-4-methoxyphenol (152 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), 
triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and DME 
(1.0 mL). Flash column chromatography (basic alumina: 20% EtOAc in hexanes) afforded the title 
compound (3e) as a white solid (92 mg, 0.26 mmol, 52% yield). mp: 88-95 °C; IR max/cm-1 (film): 3061, 
2979, 2947, 2846, 2497, 2161, 2042, 1848, 1584, 1561, 1486, 1468, 1437, 1409, 1257, 1205, 1043, 875, 
776, 694; 1H NMR (400 MHz, CDCl3) : 8.54 (1H, d, J = 5.6 Hz), 7.98-7.88 (2H, m), 7.50-7.36 (4H, m), 
7.24 (1H, d, J = 2.3 Hz), 7.08 (1H, dd, J = 8.9, 2.9 Hz), 6.95 (1H, d, J = 9.0 Hz), 6.75 (1H, dd, J = 5.6, 2.3 
Hz), 3.93 (3H, s); 13C NMR (100 MHz, CDCl3) 











Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 5,6,7,8-tetrahydronaphthalen-2-ol (111.2 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), 
triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF 
(1.0 mL). Flash column chromatography by dissolving in CH2Cl2 and dry loading (basic alumina: 2% 
EtOAc in hexanes) afforded the title compound (3f) as a white solid (122 mg, 0.41 mmol, 81% yield). mp: 
57-61 °C; IR max/cm-1 (film): 3061, 2925, 2835, 2162, 1579, 1561, 1492, 1469, 1238, 1195, 865, 773, 691; 
1H NMR (400 MHz, CDCl3) : 8.51 (1H, d, J = 5.7 Hz), 7.94-7.89 (2H, m), 7.49-7.37 (3H, m), 7.27 (1H, 
d, J = 2.3 Hz), 7.11 (1H, d, J = 8.2 Hz), 6.88-6.82 (2H, m), 6.77 (1H, dd, J = 5.6, 2.4 Hz), 2.82-2.74 (4H, 
m), 1.88-1.77 (4H, m); 13C NMR (100 MHz, CDCl3) 
C










Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), N-(4-hydroxyphenyl)acetamide (151.2 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), 
triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and DME 
(1.0 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt3: 
1% MeOH in DCM) afforded the title compound (3g) as a white solid (111 mg, 0.36 mmol, 73% yield). 
mp: 129-139 °C; IR max/cm-1 (film): 3297, 3206, 3064, 2923, 2852, 1659, 1546, 1501, 1469, 1405, 1302, 
1211, 1016, 911, 849, 776, 693; 1H NMR (400 MHz, CDCl3) : 8.53 (1H, d, J = 5.6 Hz), 7.93-7.87 (2H, 
m), 7.60-7.54 (2H, m), 7.48-7.37 (3H, m), 7.32 (1H, br), 7.25 (1H, d, J = 2.2 Hz) 7.13-7.07 (2H, m), 6.77 
(1H, dd, J = 5.7, 2.4 Hz), 2.20 (3H, s); 13C NMR (100 MHz, CDCl3) 
; 








Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-((2-phenylpyridin-4-yl)oxy)phenyl)propanoate (3h) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), methyl (tert-butoxycarbonyl)-L-tyrosinate (222 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 
mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and 
THF (1.0 mL). Flash column chromatography by dissolving in CH2Cl2 and dry loading (silica gel,  gradient 
elution: 30% EtOAc in hexanes to 80% EtOAc in hexanes) afforded the title compound (3h) as a white 
solid (133.1 mg, 0.297 mmol, 59% yield). mp: 29-40 °C; IR max/cm-1 (film): 3435, 3033, 2979, 2932, 2251, 
1979, 1742, 1706, 1586, 1504, 1471, 1219, 1163, 908, 728; 1H NMR (400 MHz, CDCl3) : 8.53 (1H, d, J 
= 5.6 Hz), 7.95-7.90 (2H, m), 7.48-7.37 (3H, m), 7.27 (1H, d, J = 2.2 Hz), 7.23-7.18 (2H, m), 7.09-7.04 
(2H, m), 6.75 (1H, dd, J = 5.6, 2.4 Hz), 5.04 (1H, d, J = 7.7 Hz), 4.66-4.56 (1H, m), 3.74 (3H, s), 3.21-3.00 
(2H, m), 1.43 (9H, s); 13C NMR (100 MHz, CDCl3) 










Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzenethiol (77 L, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography (silica gel: 2.5% EtOAc in hexanes) afforded the title compound (3j) as a clear oil 
(109 mg, 0.42 mmol, 83% yield).  IR max/cm-1 (film):  3689, 3064, 3040, 2997, 2921, 2850, 2612, 2459, 
2162, 1977, 1814, 1764, 1699, 1567, 1534, 1462, 1379, 757, 693; 1H NMR (400 MHz, CDCl3) : 8.43 (1H, 
d, J = 5.3 Hz), 7.89-7.84 (2H, m), 7.63-7.56 (2H, m), 7.50-7.36 (7H, m), 6.88 (1H, dd, J = 5.3, 1.8 Hz); 13C 
NMR (100 MHz, CDCl3) 
; m/z LRMS 
(ESI + APCI) found [M+H]+ 264.1, C17H14NS+  requires 264.1. 
4-((4-Chlorophenyl)thio)-2-phenylpyridine (3n) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-chlorobenzenethiol (109 mg, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
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trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 2.5% EtOAc in Toluene) afforded the title compound (3n) as a white chrystalline solid (109 mg, 0.37 
mmol, 73% yield). mp: 86-90 °C IR max/cm-1 (film): 3076, 3044, 3012, 2924, 2771, 2464, 1980, 1812, 
1585, 1536, 1461, 1378, 1089, 836.8, 797, 690; 1H NMR (400 MHz, CDCl3) : 8.46 (1H, d, J = 5.3 Hz), 
7.89-7.85 (2H, m), 7.54-7.49 (2H, m), 7.48-7.38 (6H, m), 6.87 (1H, dd, J = 5.3, 1.8 Hz); 13C NMR (100 
MHz, CDCl3) ; 
m/z LRMS (ESI + APCI) found [M+H]+ 298.1, C17H13ClNS+  requires 298.0. 
4-((4-Fluorophenyl)thio)-2-phenylpyridine (3m) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-fluorobenzenethiol (80 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 2.5% EtOAc in Toluene) afforded the title compound (3m) as a white solid (110 mg, 0.39 mmol, 78% 
yield). mp: 75-79 °C; IR max/cm-1 (film): 3090, 3067, 3037, 2923, 2853, 2466, 2040, 1813, 1702, 1585, 
1570, 1537, 1489, 1223, 776; 1H NMR (400 MHz, CDCl3) : 8.44 (1H, d, J = 5.3 Hz), 7.92-7.83 (2H, m), 
7.65-7.55 (2H, m), 7.48-7.35 (4H, m), 7.22-7.13 (2H, m), 6.83 (1H, dd, J = 5.3, 1.7 Hz); 13C NMR (100 
MHz, CDCl3) 163.7 (d, J = 251 Hz), 157.5, 150.9, 149.4, 138.9, 137.5 (d, J = 8.5 Hz), 129.2, 128.7, 
126.9, 124.8 (d, J = 3.5 Hz), 118.96, 117.43, 117.23 (d, J = 21.9 Hz); 19F NMR (365 MHz, 






Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenethiol (177 mg, 0.75 mmol), 
triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF 
(1.0 mL). Flash column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 8% EtOAc in 
hexanes) afforded the title compound (3o) as a yellow oil (119.4 mg, 0.307 mmol, 61% yield).  IR max/cm-
1 (film): 2979, 2928, 2247, 2216, 1715, 1569, 1358, 1142, 907, 729; 1H NMR (400 MHz, CDCl3) : 8.44 
(1H, d, J = 5.3 Hz), 7.90-7.85 (4H, m), 7.60-7.53 (2H, m), 7.50-7.36 (4H, m), 6.90 (1H, dd, J = 5.3, 1.7 
Hz), 1.37 (12H, s); 13C NMR (100 MHz, CDCl3) 
; m/z 










Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 2-methoxybenzenethiol (91 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 10% EtOAc in hexanes) afforded the title compound (3k) as a clear oil (115 mg, 0.39 mmol, 79% 
yield).  IR max/cm-1 (film): 3062, 2936, 2835, 2167, 1567, 1476, 1462, 1274, 1247, 1022, 753; 1H NMR 
(400 MHz, CDCl3) : 8.41 (1H, d, J = 5.3 Hz), 7.89-7.84 (2H, m), 7.60-7.54 (1H, m), 7.52-7.36 (5H, m), 
7.08-7.00 (2H, m), 6.83 (1H, dd, J = 5.3, 1.8 Hz), 3.84 (3H, s); 13C NMR (100 MHz, CDCl3) 

; m/z LRMS (ESI + APCI) found [M+H]+ 294.2, C18H16NOS+  requires 294.1. 
4-((2-Bromophenyl)thio)-2-phenylpyridine (3l) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 2-bromobenzenethiol (90 L, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
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column chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 20% EtOAc in hexanes) 
afforded the title compound (3l) as a brown oil (144 mg, 0.42 mmol, 84% yield).  IR max/cm-1 (film): 3056, 
2925, 2456, 2162, 1979, 1567, 1536, 1444, 1379, 752, 693; 1H NMR (400 MHz, CDCl3) : 8.49 (1H, d, J 
= 5.3 Hz), 7.91-7.86 (2H, m), 7.77 (1H, dd, J = 7.8, 1.2 Hz), 7.64 (1H, dd, J = 7.8, 1.7 Hz), 7.50-7.35 (5H, 
m), 7.35-7.29 (1H, m), 6.88 (1H, dd, J = 5.3, 1.8 Hz); 13C NMR (100 MHz, CDCl3) 
; 
m/z LRMS (ESI + APCI) found [M+H]+ 342.1, C17H13BrNS+  requires 342.0. 
4-((3-Methoxyphenyl)thio)-2-phenylpyridine (3p) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 3-methoxybenzenethiol (93 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 10% EtOAc in hexanes) afforded the title compound (3p) as a yellow oil (118 mg, 0.40 mmol, 80% 
yield). IR max/cm-1 (film): 3001, 2933, 2834, 1566, 1479, 1231, 772, 690; 1H NMR (400 MHz, CDCl3) : 
8.44 (1H, d, J = 5.3 Hz), 7.90-7.85 (2H, m), 7.47-7.34 (5H, m), 7.17 (1H, d, J = 7.6 Hz), 7.13-7.10 (1H, 
m), 7.00 (1H, dd, J = 8.3, 2.6 Hz), 6.90 (1H, dd, J = 5.3, 1.7 Hz), 3.83 (3H, s); 13C NMR (100 MHz, CDCl3) 







Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 3-(trifluoromethoxy)benzenethiol (146 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), 
triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.5 mmol) and THF (1.0 
mL). Flash column chromatography (silica gel: 15% EtOAc in hexanes) afforded the title compound (3q) 
as a clear oil (81.8 mg, 0.235 mmol, 47% yield).  IR max/cm-1 (film): 2925, 2853, 2218, 1568, 1251, 1219, 
1205, 1165, 907, 730, 692; 1H NMR (400 MHz, CDCl3) : 8.49 (1H, dd, J = 5.3, 0.5 Hz), 7.90-7.85 (2H, 
m), 7.52-7.38 (7H, m), 7.34-7.28 (1H, m), 6.93 (1H, dd, J = 5.3, 1.8 Hz); 13C NMR (100 MHz, CDCl3) 
q, J = 
258.2 Hz), 119.9, 118.5; 19F NMR (365 MHz, CDCl3)m/z LRMS (ESI + APCI) found [M+H]+ 
348.1, C18H13F3NOS+ requires 348.1. 
4-((2,6-Dimethylphenyl)thio)-2-phenylpyridine (3r) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 2,6-dimethylbenzenethiol (100 L, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
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phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography (silica gel: 2% EtOAc in toluene) afforded the title compound (3r) as a clear oil 
(108 mg, 0.37 mmol, 74% yield).  IR max/cm-1 (film): 3054, 2958, 2922, 2459, 2161, 1948, 1727, 1567, 
1535, 1460, 1375, 1103, 770,  693; 1H NMR (400 MHz, CDCl3) : 8.35 (1H, d, J = 5.3 Hz), 7.84-7.79 (2H, 
m), 7.44-7.32 (3H, m), 7.30-7.17 (4H, m), 6.63 (1H, dd, J = 5.3, 1.8 Hz), 2.41 (6H, s); 13C NMR (100 MHz, 
CDCl3); 
m/z LRMS (ESI + APCI) found [M+H]+ 292.2, C19H18NS+  requires 292.1. 
2-Phenyl-4-(thiophen-2-ylthio)pyridine (3s) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), thiophene-2-thiol (70 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 2.5% EtOAc in toluene) afforded the title compound (3s) as a tan oil (93 mg, 0.35 mmol, 69% yield).  
IR max/cm-1 (film): 3062, 3036, 2993, 2923, 2360, 2162, 1952, 1567, 1379, 1072, 771, 691; 1H NMR (400 
MHz, CDCl3) : 8.46 (1H, d, J = 5.3 Hz), 7.90-7.85 (2H, m), 7.63 (1H, dd, J = 5.3, 1.2 Hz), 7.48-7.37 (5H, 
m), 7.19 (1H, dd, J = 5.3, 3.5 Hz), 6.89 (1H, dd, J = 5.3, 1.8 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS 







Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzeneselenol (80 L, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 5% EtOAc in hexanes) 
afforded the title compound (3i) as a white solid (141 mg, 0.45 mmol, 91% yield). mp: 43-47 °C; IR max/cm-
1 (film): 3064, 3033, 2923, 2452, 2163, 1961, 1891, 1753, 1562, 1534, 1438, 1379, 1019, 825, 774, 738, 
698, 679; 1H NMR (400 MHz, CDCl3) : 8.41 (1H, d, J = 5.2 Hz), 7.90-7.84 (2H, m), 7.71-7.65 (2H, m), 
7.58 (1H, d, J = 1.1 Hz), 7.50-7.36 (6H, m), 7.04 (1H, dd, J = 5.3, 1.6 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS 
(ESI + APCI) found [M+H]+ 312.2, C17H14NSe+  requires 312.0. 
N-Methyl-N,2-diphenylpyridin-4-amine (3u) 
 
Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 470 µL, 0.75 mmol), 
N-methylaniline (81 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
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trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica 
gel: 20% EtOAc in hexanes) afforded the title compound (3u) as a tan powder (117 mg, 0.45 mmol, 90% 
yield). mp: 77-82 °C; IR max/cm-1 (film): 3061, 3045, 3038, 2917, 2852, 2818, 2592, 2501, 2161, 2050, 
1953, 1842, 1603, 1597, 1536, 1480, 1445, 1360, 1235, 1135, 983, 825, 760, 693; 1H NMR (400 MHz, 
CDCl3) : 8.32 (1H, d, J = 5.8 Hz), 7.88-7.83 (2H, m), 7.52-7.33 (5H, m), 7.31-7.24 (3H, m),  6.99 (1H, d, 
J = 2.4 Hz), 6.54 (1H, dd, J = 8.4, 3.4 Hz), 3.39 (3H, s); 13C NMR (100 MHz, CDCl3) 
; m/z 







Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 µL, 0.38 mmol), 
3-ethoxy-N-methylaniline (57 mg, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 60% EtOAc in hexanes) afforded the title compound (3v) as an orange oil (63 mg, 0.20 mmol, 81% 
yield). IR max/cm-1 (film): 2978, 2928, 2162, 1574, 1543, 1478, 1446,. 1245, 1203, 1046, 984, 773, 695; 
1H NMR (400 MHz, CDCl3) : 8.32 (1H, d, J = 5.8 Hz), 7.90-7.84 (2H, m), 7.46-7.30 (4H, m), 7.01 (1H, 
d, J = 2.4 Hz), 6.86-6.77 (3H, m), 6.56 (1H, dd, J = 5.9, 2.5 Hz), 4.04 (2H, q, J = 6.9 Hz), 3.37 (3H, s), 1.42 
(3H, t, J = 6.9 Hz); 13C NMR (100 MHz, CDCl3) 






Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 µL, 0.38 mmol), 
N-benzylaniline (65 L, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 20% EtOAc in hexanes) afforded the title compound (3w) as an orange amorphous solid (52 mg, 0.15 
mmol, 62% yield). IR max/cm-1 (film): 3062, 2961, 2930, 2860, 2253, 1715, 1588, 1496, 1385, 1271, 1120, 
904, 725, 649; 1H NMR (400 MHz, CDCl3) : 8.28 (1H, d, J = 5.9 Hz), 7.79-7.74 (2H, m), 7.46-7.31 (11H, 
m), 7.30-7.26 (2H, m),  7.01 (1H, d, J = 2.4 Hz), 6.55 (1H, dd, J = 5.9, 2.5 Hz), 5.03 (2H, s); 13C NMR (100 
MHz, CDCl3) 

; m/z LRMS (ESI + APCI) found [M+H]+ 337.2, C24H21N2+  requires 337.2.
1-(2-Phenylpyridin-4-yl)indoline (3x) 
 
Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 0.47 mL, 0.75 mmol), 
indoline (84.1 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate 
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(282.5 mg, 0.5 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) 
afforded the title compound (3x) as a brown oil (92.3 mg, 0.339 mmol, 68% yield). IR max/cm-1 (film): 
2978, 2928, 2162, 1574, 1543, 1478, 1446, 1245, 1203, 1046, 984, 773, 695; 1H NMR (400 MHz, CDCl3) 
: 8.51 (1H, d, J = 5.8 Hz), 7.99-7.94 (2H, m), 7.51-7.45 (3H, m), 7.45-7.37 (2H, m), 7.26-7.16 (2H, m), 
7.02 (1H, dd, J = 5.8, 2.3 Hz), 6.94-6.88 (1H, m), 4.07 (2H, t, J = 8.3 Hz), 3.21 (2H, t, J = 8.3 Hz); 13C 
NMR (100 MHz, CDCl3) 







Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 µL, 0.375 mmol), 
6-bromoindoline (74 mg, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 30% EtOAc in hexanes) afforded the title compound (3y) as a white solid (36 mg, 0.10 mmol, 41% 
yield). mp: 75-80°C; IR max/cm-1 (film): 3298, 3035, 2956, 2162, 1608, 1574, 1478, 1431, 1270, 988, 
769.5, 691.4; 1H NMR (400 MHz, CDCl3) : 8.54 (1H, d, J = 5.8 Hz), 7.99-7.94 (2H, m), 7.52-7.38 (5H, 
m), 7.10-7.06 (1H, m), 7.05-6.99 (2H, m), 4.09 (2H, t, J = 8.4 Hz), 3.15 (2H, t, J = 8.4 Hz); 13C NMR (100 
MHz, CDCl3) 






Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), pyrrole (52 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by 
dissolving in CH2Cl2 and dry loading (silica gel: 10% EtOAc in hexanes) afforded the title compound (3ap) 
as a clear oil (81 mg, 0.37 mmol, 74% yield). IR max/cm-1 (film): 3063, 2925, 2852, 2360, 2340, 2246, 
2218, 1718, 1594, 1494, 1351, 1256, 1066, 1176, 905, 723; 1H NMR (400 MHz, CDCl3) : 8.66 (1H, d, J 
= 5.2 Hz), 8.00 (2H, d, J = 7.3 Hz), 7.69 (1H, d, J = 1.6 Hz), 7.53-7.41(3H, m), 7.29-7.20 (3H, m), 6.42 
(2H, t, J = 1.9 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + APCI) 
found [M+H]+ 221.1, C15H13N2+  requires 221.1. 
4-(1H-Imidazol-1-yl)-2-phenylpyridine (3ar) 
 
Prepared according to general procedure D using potassium hydride (36.3% dispersion in mineral oil, 41 
mg, 0.38 mmol), 18-crown-6 (99 mg, 0.38 mmol) was added at the start with potassium hydride, 1H-
imidazole (26 mg, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate 
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(141 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel was packed with hexanes 
and neutralized with NEt3, gradient elution: 60% EtOAc in hexanes to 80% EtOAc in hexanes) afforded the 
title compound (3ar) as a clear oil (28 mg, 0.13 mmol, 51% yield). IR max/cm-1 (film): 3123, 3062, 2924, 
2851, 2222, 1979, 1595, 1568, 1496, 1240, 1054, 905, 725, 693; 1H NMR (400 MHz, CDCl3) : 8.78 (1H, 
d, J = 5.4 Hz); 8.08 (1H, s), 8.05-8.00 (2H, m), 7.73 (1H, d, J = 1.9 Hz), 7.55-7.44 (4H, m), 7.31-7.26 (2H, 
m); 13C NMR (100 MHz, 
CDCl3); m/z LRMS 
(ESI + APCI) found [M+H]+ 222.1, C14H12N3+  requires 222.1. 
2-Phenyl-4-(1H-pyrazol-1-yl)pyridine (3aq) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 1H-pyrazole (51 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 15% EtOAc in hexanes) 
afforded the title compound (3aq) as a clear oil (80 mg, 0.36 mmol, 72% yield). IR max/cm-1 (film): 3032, 
1591, 1568, 1521, 1482, 1442, 1395, 1381, 1041, 774, 693; 1H NMR (400 MHz, CDCl3) : 8.72 (1H, d, J 
= 5.4 Hz); 8.20-8.00 (4H, m), 7.80 (1H, d, J = 1.4 Hz), 7.59-7.40 (4H, m), 6.58-6.53 (1H, dd, J = 2.4, 1.8 
Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + 





Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-bromo-1H-pyrazole (110 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 10% EtOAc in hexanes) 
afforded the title compound (3as) as a white solid (97 mg, 0.32 mmol, 64% yield). mp: 140-143 °C; IR 
max/cm-1 (film): 3142, 3116, 3029, 2921, 1928, 1694, 1593, 1569, 1478, 1447, 1414, 1406, 1339, 1251, 
1148, 954, 777, 703; 1H NMR (400 MHz, CDCl3) : 8.74 (1H, d, J = 5.4 Hz); 8.12 (1H, s), 8.10-8.02 (3H, 
m), 7.76 (1H, s), 7.56-7.43 (4H, m); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + 
APCI) found [M+H]+ 300.1, C14H11BrN3+  requires 300.0. 
4-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-phenylpyridine (3at) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 3,5-dimethyl-1H-pyrazole (72 mg, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium 
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trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by 
dissolving in CH2Cl2 and dry loading (silica gel: 30% EtOAc in hexanes) afforded the title compound (3at) 
as a clear oil (47 mg, 0.19 mmol, 37% yield). IR max/cm-1 (film): 2925, 2225, 1710, 1593, 1573, 905, 727; 
1H NMR (400 MHz, CDCl3) : 8.73 (1H, d, J = 5.4 Hz), 8.06-8.01 (2H, m), 7.92 (1H, d, J = 1.7 Hz), 7.51-
7.40 (3H, m), 7.38 (1H, dd, J = 5.4, 2.0 Hz), 6.08 (1H, m), 2.50 (3H, s), 2.32 (3H, s); 13C NMR (100 MHz, 
CDCl3); 
m/z LRMS (ESI + APCI) found [M+H]+ 250.2, C16H16N3+  requires 250.1. 
2-Phenyl-4-(4-phenyl-1H-imidazol-1-yl)pyridine (3au) 
 
Prepared according to general procedure D using potassium hydride (36.3% dispersion in mineral oil, 83 
mg, 0.75 mmol), 4-phenylimidazole (108 mg, 0.75 mmol), 18-Crown-6 (198 mg, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.5 mmol) and THF (1.0 mL). Flash 
column chromatography (silica gel was packed with hexanes and neutralized with NEt3: 40% EtOAc in 
hexanes) afforded the title compound (3au) as a yellow oil (38 mg, 0.13 mmol, 25% yield). IR max/cm-1 
(film): 3058, 2924, 2360, 2341, 2217, 1592, 1568, 1493, 1445, 1238, 1056, 726, 692, 906; 1H NMR (400 
MHz, CDCl3) : 8.78 (1H, d, J = 5.4 Hz), 8.11 (1H, s), 8.04 (2H, d, J = 6.9 Hz), 7.86 (2H, d, J = 7.3 Hz), 
7.76 (1H, d, J = 1.6 Hz), 7.71 (1H, s), 7.56-7.39 (5H, m), 7.35-7.28 (2H, m); 13C NMR (100 MHz, CDCl3) 
C), 138.3, 135.1, 133.0, 129.8, 128.9, 128.7, 127.6, 127.0, 125.1, 112.8, 112.1, 





Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), (3-cyanopyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (257 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 50% EtOAc in hexanes) afforded the title compound (3z) as a colorless 
amorphous solid (90.9 mg, 0.402 mmol, 80% yield).  IR max/cm-1 (film): 3062, 2973, 2936, 2839, 2232, 
1585, 1567, 1502, 1481, 1277, 1242, 1195, 1179, 1027, 889, 838; 1H NMR (400 MHz, CDCl3) : 8.77 (1H, 
s), 8.51 (1H, d, J = 5.9 Hz), 7.95-7.10-7.03 (2H, m), 7.00-6.95 (2H, m), 6.64 (1H, d, J = 5.9 Hz), 3.84 (3H, 
s); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + APCI) 
found [M+H]+ 227.1, C13H11N2O2+  requires 227.1. 
4-(Methyl(phenyl)amino)nicotinonitrile (3am) 
 
Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 470 µL, 0.75 mmol), 
N-methylaniline (81 L, 0.75 mmol), (3-cyanopyridin-4-yl)triphenylphosphonium 
trifluoromethanesulfonate (257 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica 
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gel: 20% EtOAc in hexanes) afforded the title compound (3am) as an orange amorphous solid (86 mg, 0.41 
mmol, 82% yield). IR max/cm-1 (film): 3018, 2920, 2855, 2208, 1600, 1582, 1495, 1405, 1203, 1051, 809, 
698; 1H NMR (400 MHz, CDCl3) : 8.47 (1H, s), 8.31 (1H, d, J = 6.2 Hz), 7.50-7.42 (2H, m), 7.42-7.33 
(1H, m), 7.25-7.20 (2H, m), 6.65 (1H, d, J = 6.2 Hz), 3.52 (3H, s); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + APCI) 
found [M+H]+ 210.1, C13H12N3+  requires 210.1. 
3-Phenyl-4-(phenylthio)pyridine (3af) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzenethiol (77 L, 0.75 mmol), triphenyl(3-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica 
gel: 10% EtOAc in toluene) afforded the title compound (3af) as a clear oil (101.2 mg, 0.384 mmol, 77% 
yield).  IR max/cm-1 (film): 3066, 3035, 2997, 2923, 2950, 2612, 1980, 1815, 1763, 1699, 1567, 1462, 1379, 
757, 693; 1H NMR (400 MHz, CDCl3) : 8.37 (1H, s), 8.25 (1H, d, J = 5.4 Hz), 7.54-7.38 (10H, m), 6.68 
(1H, d, J = 5.4 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS 








Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 0.468 mL, 0.75 mmol), 
N-methylaniline (81.2 L, 0.75 mmol), triphenyl(3-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (282.6 mg, 0.5 mmol) and THF (2.0 mL). 
2-Methoxy-4-(phenylthio)pyridine (3ag) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzenethiol (77 L, 0.75 mmol), triphenyl(2-methoxypyridin-4-yl)phosphonium 
trifluoromethanesulfonate (260 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by 
dissolving in CH2Cl2 and dry loading (silica gel: 5% EtOAc in hexanes) followed by filtration through a 
plug of silica eluting with 100% DCM afforded the title compound (3ag) as a clear oil (49 mg, 0.22 mmol, 
45% yield).  IR max/cm-1 (film): 3060, 2981, 2947, 2857, 2226, 1588, 1542, 1473, 1385, 1035, 905, 728; 
1H NMR (400 MHz, CDCl3) : 7.94 (1H, d, J = 5.5 Hz), 7.57-7.51 (2H, m), 7.46-7.40 (3H, m), 6.60 (1H, 
dd, J = 5.5, 1.6 Hz) 6.33 (1H, d, J = 1.4 Hz), 3.87 (3H, s); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + APCI) found 





Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 0.47 mL, 0.75 mmol), 
N-methylaniline (81 L, 0.75 mmol), [2,2'-bipyridin]-4-yltriphenylphosphoniumtrifluoromethanesulfonate 
(283 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc, 2.5% NEt3 
in hexanes) afforded the title compound (3al) as a tan solid (107 mg, 0.41 mmol, 82% yield). mp: 107-110 
°C; IR max/cm-1 (film): 3061, 3002, 2907, 2821, 2538, 2162, 1979, 1604, 1578, 1567, 1542, 1490, 1468, 
1456, 1370, 953, 786, 774, 702; 1H NMR (400 MHz, CDCl3) : 8.60 (1H, d, J = 4.1 Hz),  8.32 (1H, d, J = 
8.0 Hz), 8.22 (1H, d, J = 5.8 Hz), 7.80-7.70 (2H, m), 7.45-7.35 (2H, m), 7.25-7.15 (4H, m), 6.52 (1H, dd, 
J = 5.8, 2.6 Hz), 3.41 (3H, s); 13C NMR (100 MHz, CDCl3) 
; 
m/z LRMS (ESI + APCI) found [M+H]+ 262.1, C17H16N3+  requires 262.1. 
4-(1H-Pyrrol-1-yl)-2,2'-bipyridine (3ax) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), 1H-pyrrole (26 L, 0.38 mmol), [2,2'-bipyridin]-4-yltriphenylphosphonium 
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trifluoromethanesulfonate (142 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (basic 
alumina: 5% EtOAc in hexanes) afforded the title compound (3ax) as a tan amorphous solid (36 mg, 0.16 
mmol, 64% yield). IR max/cm-1 (film): 3060, 2922, 2851, 2222, 1723, 1598, 1584, 1563, 1496, 1350, 1062, 
907, 723, 691; 1H NMR (400 MHz, CDCl3) : 8.72-8.69 (1H, m), 8.66 (1H, d, J = 5.4 Hz), 8.50 (1H, d, J 
= 2.2 Hz),  8.47-8.43 (1H, m), 7.85 (1H, td, J = 7.8, 1.7 Hz), 7.39-7.30 (4H, m), 6.42 (2H, t, J = 2.2 Hz); 
13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + 
APCI) found [M+H]+ 222.1, C14H12N3+  requires 222.1. 
2-(4-Methoxyphenoxy)-4-(trifluoromethyl)pyridine (3aa) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), 4-methoxyphenol (47 mg, 0.38 mmol), 15-crown-5 (75 L, 0.38 mmol), triphenyl(4-
(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (139 mg, 0.25 mmol) and THF (0.5 
mL). Flash column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 10% EtOAc in 
hexanes) afforded the title compound (3aa) as a white solid (54 mg, 0.20 mmol, 80% yield). mp: 76-79 °C; 
IR max/cm-1 (film): 3073, 3028, 2979, 2921, 2849, 2050, 1758, 1615, 1569, 1503, 1402, 1330, 1294, 1225, 
1171, 1137, 1075, 836; 1H NMR (400 MHz, CDCl3) : 8.32 (1H, d, J = 5.2 Hz), 7.16 (1H, dd, J = 5.2, 0.8 
Hz), 7.11 (1H, t, J = 1.4 Hz), 7.10-7.05 (2H, m), 6.97-6.92 (2H, m), 3.83 (3H, s); 13C NMR (100 MHz, 
CDCl3) q, J = 34.1 Hz), 122.5 (q, J = 273.1 Hz), 122.4, 114.9, 113.7 
(q, J = 3.3 Hz), 107.6 (q, J = 4.0 Hz), 55.6; 19F NMR (365 MHz, CDCl3) m/z LRMS (ESI + 






Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 1H-pyrrole (52 L, 0.75 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium 
trifluoromethanesulfonate (279 mg, 0.50 mmol), and THF (1.0 mL). Flash column chromatography by 
dissolving in CH2Cl2 and dry loading (silica gel: 2% EtOAc in hexanes) afforded the title compound (3ba) 
as a white solid (70 mg, 0.33 mmol, 66% yield).  mp: 73-77 °C; IR max/cm-1 (film): 3160, 3119, 3048, 
2922, 1724, 1615, 1575, 1492, 1437, 1352, 1330, 1300, 1276, 1172, 1128, 1059, 935, 839, 735, 675; 1H 
NMR (400 MHz, CDCl3) : 8.59 (1H, d, J = 5.1 Hz), 7.55 (2H, t, J = 2.3 Hz), 7.48 (1H, s), 7.30 (1H, dd, J 
= 0.7, 5.1 Hz), 6.39 (2H, t, J = 2.3 Hz); 13C NMR (100 MHz, CDCl3) q, J = 34.2 
Hz), 122.5 (q, J = 273.9 Hz), 118.2, 115.5 (q, J = 3.4 Hz), 112.3, 107.1 (q, J = 3.8 Hz); 19F NMR (365 MHz, 
CDCl3)  m/z LRMS (ESI + APCI) found [M+H]+ 213.1, C10H8F3N2+  requires 213.1. 
2-(1H-Pyrazol-1-yl)-4-(trifluoromethyl)pyridine (3bb) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 1H-pyrazole (51 mg, 0.75 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium 
trifluoromethanesulfonate (279 mg, 0.50 mmol), and THF (1.0 mL). Flash column chromatography by 
dissolving in CH2Cl2 and dry loading (silica gel: 3% EtOAc in hexanes) afforded the title compound (3bb), 
as a volatile clear oil (31 mg, 0.14 mmol, 29% iso. yield, 76% 1H NMR yield). Note that the product 
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evaporates during solvent evaporation. IR max/cm-1 (film): 2926, 2253, 1577, 1463, 1398, 1345, 1318, 
1179, 1149, 1040, 903, 726, 649; 1H NMR (400 MHz, CDCl3) : 8.60-8.55 (2H, m); 8.25 (1H, s), 7.78 (1H, 
d, J = 1.0 Hz), 7.39 (1H, d, J = 4.4 Hz), 6.50 (1H, t, J = 2.5 Hz); 13C NMR (100 MHz, CDCl3) 
q, J = 34.2 Hz), 127.3, 122.5 (q, J = 273.3 Hz), 116.8 (q, J = 3.4 Hz), 108.8 
(q, J = 4.0 Hz), 108.5; 19F NMR (365 MHz, CDCl3)   m/z LRMS (ESI + APCI) found [M+H]+ 
214.1, C9H7F3N3+  requires 214.1. 
2-(1H-Imidazol-1-yl)-4-(trifluoromethyl)pyridine (3bc) 
 
Prepared according to general procedure D using potassium hydride (36.3% dispersion in parafin, 83 mg, 
0.75 mmol), 1H-imidazole (51 mg, 0.75 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium 
trifluoromethanesulfonate (279 mg, 0.50 mmol), and THF (1.0 mL). Flash column chromatography (silica 
gel was packed with hexanes and neutralized with NEt3: 40% EtOAc in hexanes) afforded the title 
compound (3bc) as a white solid (78 mg, 0.37 mmol, 73% yield).  mp: 61-66 °C; IR max/cm-1 (film): 3119, 
3053, 2916, 2848, 2225, 1980, 1673, 1615, 1577, 1481, 1438, 1326, 1176, 1141, 1051, 906, 841, 652; 1H 
NMR (400 MHz, CDCl3) : 8.68 (1H, d, J = 5.1 Hz), 8.42 (1H, s), 7.68 (1H, t, J = 1.4 Hz), 7.54 (1H, s), 
7.47 (1H, dd, J = 0.6, 5.1 Hz), 7.25 (1H, t, J = 1.1 Hz); 13C NMR (100 MHz, CDCl3) 
(q, J = 34.3 Hz), 135.1, 131.4, 122.3 (q, J = 275.2 Hz), 117.5 (q, J = 3.4 Hz), 116.0, 
108.1 (q, J = 3.8 Hz); 19F NMR (365 MHz, CDCl3)  m/z LRMS (ESI + APCI) found [M+H]+ 






Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), (3-cyano-5-(3-
fluorophenyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (304 mg, 0.50 mmol) and THF 
(1.0 mL). Flash column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 25% EtOAc 
in hexanes) afforded the title compound (3ab) as a yellow solid (117 mg, 0.37 mmol, 73% yield). mp: 93-
97 °C; IR max/cm-1 (film): 3048, 3011, 2954, 2919, 2847, 2235, 1967, 1871, 1583, 1501, 1446, 1432, 1241, 
1183, 1031, 878, 794, 696; 1H NMR (400 MHz, CDCl3) : 8.79 (1H, s), 8.75 (1H, s), 7.40-7.33 (1H, m), 
7.24-7.20 (1H, m), 7.19-7.15 (1H, m), 7.10-7.04 (1H, m), 6.84-6.76 (4H, m), 3.76 (3H, m); 13C NMR (100 
MHz, CDCl3) d, J = 246.2 Hz), 161.8, 156.7, 155.2, 154.7, 149.6, 134.4 (d, J = 8.1 Hz), 130.3 (d, 
J = 8.4 Hz), 129.5, 124.9 (d, J = 3.1 Hz), 119.0, 116.3 (d, J = 22.7 Hz), 115.8 (d, J = 21.0 Hz), 114.8, 113.3, 
103.5, 55.6; 19F NMR (365 MHz, CDCl3)m/z LRMS (ESI + APCI) found [M+H]+ 321.2, 










Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzenethiol (77 L, 0.75 mmol), (3-cyano-5-(thiophen-3-yl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (298 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 20% EtOAc in hexanes) afforded the title compound (3ah) as white solid (121 
mg, 0.31 mmol, 63% yield). mp: 129-133 °C; IR max/cm-1 (film): 3734, 3111, 3054, 2924, 2498, 2232, 
1968, 1867, 1725, 1543, 1438, 1077, 842, 787, 736, 656; 1H NMR (400 MHz, CDCl3) : 8.74 (1H, s), 8.67 
(1H, s), 7.39-7.34 (1H, m), 7.34-7.29 (1H, m), 7.26-7.18 (4H, m), 7.18-7.12 (2H, m); 13C NMR (100 MHz, 
CDCl3) ; 
m/z LRMS (ESI + APCI) found [M+H]+ 295.1, C16H11N2S2+  requires 295.0. 
5-(3-Fluorophenyl)-4-(1H-pyrrol-1-yl)nicotinonitrile (3ay) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), 1H-pyrrole (26 L, 0.38 mmol), (3-cyano-5-(3-fluorophenyl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (152 mg, 0.25 mmol) and THF (0.5 mL). Flash column 
chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 10% EtOAc in hexanes) afforded the 
title compound (3ay) as a brown oil (17 mg, 0.063 mmol, 25% yield). IR max/cm-1 (film): 3019, 2927, 2236, 
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1613, 1587, 1496, 1485, 1324, 1215, 1063, 907, 729, 696, 668; 1H NMR (400 MHz, CDCl3) : 8.95 (1H, 
s); 8.84 (1H, s), 7.37-7.30 (1H, m), 7.09 (1H, td, J = 8.4, 2.6 Hz), 6.85 (1H, d, J = 7.7 Hz), 6.75 (1H, dt, J 
= 9.3, 1.8 Hz), 6.64 (2H, t, J = 2.1 Hz), 6.30 (2H, t, J = 2.1 Hz); 13C NMR (100 MHz, CDCl3) d, 
J = 248.0 Hz), 155.1, 153.8, 147.2, 135.4 (d, J = 8.1 Hz), 132.3, 130.7 (d, J = 8.4 Hz), 124.0 (d, J = 3.1 
Hz), 121.5, 116.1 (d, J = 21.0 Hz), 115.3 (d, J = 22.9 Hz), 114.6, 112.0, 107.3; 19F NMR (365 MHz, 
CDCl3) m/z LRMS (ESI + APCI) found [M+H]+ 264.1, C16H11FN3+  requires 264.1. 
4-(Phenylthio)-5,6,7,8-tetrahydroquinoline (3ai) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzenethiol (76.5 L, 0.75 mmol), triphenyl(5,6,7,8-tetrahydroquinolin-4-yl)phosphonium 
trifluoromethanesulfonate (272mg, 0.50 mmol) and DME (1.0 mL). Flash column chromatography (silica 
gel: 30% EtOAc in toluene) afforded the title compound (3ai) as a white solid (93 mg, 0.39 mmol, 77% 
yield). mp: 93-98 °C, IR max/cm-1 (film): 3034, 2861, 2658, 2535, 2184, 1981, 1880, 1724, 1555, 1433, 
1402, 1064, 815, 755, 704, 688; 1H NMR (400 MHz, CDCl3) : 8.05 (1H, d, J = 5.3 Hz), 7.55-7.42 (5H, 
m), 6.41 (1H, d, J = 5.3 Hz), 2.91 (2H, t, J = 8.0 Hz), 2.73 (2H, t, J = 8.0 Hz), 1.94-1.84 (4H, m); 13C NMR 
(100 MHz, CDCl3) ; 








Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 468 µL, 0.75 mmol), 
N-methylaniline (81 L, 0.75 mmol), (5-cyano-2-isopropylpyridin-4-yl)triphenylphosphonium 
trifluoromethanesulfonate (278 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography by 
dissolving in CH2Cl2 and dry loading (silica gel: 20% EtOAc in hexanes) afforded the title compound (3an) 
as an off-white powder (87 mg, 0.35 mmol, 69% yield). mp: 108-114 °C; IR max/cm-1 (film): 3060, 3007, 
2963, 2921, 2868, 2214, 1863, 1752, 1581, 1534, 1492, 1410, 1310, 1051, 877, 698; 1H NMR (400 MHz, 
CDCl3) : 8.43 (1H, s), 7.48-7.42 (2H, m), 7.37-7.31 (1H, m), 7.24-7.19 (2H, m), 6.54 (1H, s), 3.49 (3H, 
s), 2.93 (1H, sp, J = 6.8 Hz), 1.26 (6H, d, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + 
APCI) found [M+H]+ 252.2, C16H18N3+  requires 252.1. 
2-(4-Methoxyphenoxy)-4-methylquinoline (3ac) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), (4-methylquinolin-
2-yl)triphenylphosphonium trifluoromethanesulfonate (277 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography by dissolving in CH2Cl2 and dry loading (basic alumina: 5% EtOAc in hexanes) 
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afforded the title compound (3ac) as a white solid (90 mg, 0.34 mmol, 68% yield). mp: 96-100 °C; IR 
max/cm-1 (film): 3067, 2952, 2920, 2835, 2163, 1615, 1575, 1503, 1463, 1442, 1384, 1336, 1201, 1177, 
1022, 828, 756; 1H NMR (400 MHz, CDCl3) : 7.90 (1H, dd, J = 8.3, 1.2 Hz), 7.79 (1H, dd, J = 8.4, 0.7 
Hz), 7.62-7.57 (1H, m), 7.45-7.40 (1H, m), 7.19-7.14 (2H, m), 6.97-6.92 (2H, m), 6.89 (1H, d, J = 0.8 Hz), 
3.84 (3H, s), 2.66 (3H, s); 13C NMR (100 MHz, CDCl3) 
; 
m/z LRMS (ESI + APCI) found [M+H]+ 266.1, C17H16NO2+  requires 266.1. 
2-(Phenylthio)-4-(thiophen-3-yl)-7-(trifluoromethyl)quinoline (3aj) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), benzenethiol (38 L, 0.38 mmol), triphenyl(4-(thiophen-3-yl)-7-(trifluoromethyl)quinolin-2-
yl)phosphonium trifluoromethanesulfonate (172 mg, 0.25 mmol) and THF (0.5 mL). Flash column 
chromatography (silica gel: 40% DCM in hexanes) afforded the title compound (3aj) as a white powder (71 
mg, 0.18 mmol, 74% yield). mp: 89-93 °C; IR max/cm-1 (film): 3103, 2923, 2852, 2161, 1792, 1586, 1334, 
1288, 1156, 1116, 1097, 1062, 829, 769; 1H NMR (400 MHz, CDCl3) : 8.24 (1H, s), 8.05 (1H, d, J = 8.7 
Hz), 7.71-7.66 (2H, m), 7.58 (1H, dd, J = 8.8, 1.8 Hz), 7.51-7.45 (4H, m), 7.42 (1H, dd, J = 2.9, 1.2 Hz), 
7.21 (1H, dd, J = 5.0, 1.2 Hz), 7.12 (1H, s); 13C NMR (100 MHz, CDCl3) 
q, J = 33.1 Hz), 129.9, 129.7, 129.5, 128.5, 126.9, 126.7, 126.5 
(q, J = 4.4 Hz), 126.4, 125.5, 123.9( q, J = 272.1 Hz), 121.3 (q, J = 3.2 Hz), 120.8; 19F NMR (365 MHz, 






Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), (5-bromo-2-(methylthio)pyrimidin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (307 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound (3ad) as a white solid (142 
mg, 0.44 mmol, 87% yield). mp: 86-88 °C; IR max/cm-1 (film): 3024, 3006, 2926, 2836, 1554, 1537, 1501, 
1407, 1332, 1288, 1256, 1221, 1176, 1031, 957, 822, 760; 1H NMR (400 MHz, CDCl3) : 8.45 (1H, s), 
7.11-7.06 (2H, m), 6.94-6.89 (2H, m), 3.83 (3H, s), 2.26 (3H, s); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI + APCI) found 
[M+H]+ 327.0, C12H12BrN2O2S+  requires 327.0. 
5-(4-Methoxyphenyl)-4-(phenylthio)pyrimidine (3ak) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), benzenethiol (77 L, 0.75 mmol), (5-(4-methoxyphenyl)pyrimidin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (298 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 20% EtOAc in hexanes) afforded the title compound (3ak) as a white powder 
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(98 mg, 0.33 mmol, 66% yield).  mp: 98-101 °C; IR max/cm-1 (film): 3074, 3009, 2936, 2835, 2545, 2162, 
2061, 1575, 1522, 1509, 1379, 1293, 1252, 1176, 747; 1H NMR (400 MHz, CDCl3) : 8.76 (1H, s); 8.31 
(1H, s), 7.56-7.50 (2H, m), 7.49-7.41 (5H, m), 7.09-7.03 (2H, m), 3.90 (3H, s); 13C NMR (100 MHz, CDCl3) 
; m/z LRMS (ESI 
+ APCI) found [M+H]+ 295.1, C17H15N2OS+  requires 295.1. 
5-(4-Methoxyphenyl)-4-(1H-pyrrol-1-yl)pyrimidine (3az) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), 1H-pyrrole (26 L, 0.38 mmol), (5-(4-methoxyphenyl)pyrimidin-4-yl)triphenylphosphonium 
trifluoromethanesulfonate (149 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica 
gel: 20% EtOAc in hexanes) afforded the title compound (3az) as a white powder (52 mg, 0.21 mmol, 82% 
yield). mp: 100-105 °C; IR max/cm-1 (film): 3158, 3121, 3058, 2924, 2840, 1610, 1578, 1551, 1442, 1393, 
1349, 1248, 1178, 1059, 931, 835, 731; 1H NMR (400 MHz, CDCl3) : 8.98 (1H, d, s), 8.60 (1H, s), 7.24-
7.19 (2H, m), 7.04( 2H, t, J = 2.3 Hz), 7.00-6.95 (2H, m), 6.18 (2H, t, J = 2.3 Hz), 3.87 (3H, s); 13C NMR 
(100 MHz, CDCl3) C), 157.1, 154.6, 130.0, 126.8, 124.4, 120.7, 114.7, 111.4, 55.3; m/z LRMS 








Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 
0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 L, 0.75 mmol), 
triphenyl(quinoxalin-2-yl)phosphonium trifluoromethanesulfonate (270 mg, 0.50 mmol) and THF (1.0 
mL). Flash column chromatography by dissolving in CH2Cl2 and dry loading (silica gel: 10% EtOAc in 
hexanes) afforded the title compound (3ae) as a white amorphous solid (100 mg, 0.40 mmol, 79% yield). 
IR max/cm-1 (film): 3060, 3022, 2953, 2931, 2836, 2599, 2042, 1887, 1830, 1641, 1574, 1499, 1401, 1306, 
1251, 1205, 1182, 993, 917, 829, 759; 1H NMR (400 MHz, CDCl3) : 8.67 (1H, s), 8.05 (1H, dd, J = 8.0, 
1.7 Hz), 7.78-7.74 (1H, m), 7.68-7.57 (2H, m), 7.23-7.18 (2H, m), 7.00-6.95 (2H, m), 3.86 (3H, s); 13C 
NMR (100 MHz, 
CDCl3); m/z 
LRMS (ESI + APCI) found [M+H]+ 253.2, C15H13N2O2+  requires 253.1. 
2-(Bis(3-(trifluoromethyl)phenyl)methyl)-4-(1H-pyrrol-1-yl)pyridine (3be) 
 
Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.375 mmol), 1H-pyrrole (26 L, 0.38 mmol), (2-(bis(3-(trifluoromethyl)phenyl)methyl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (198 mg, 0.25 mmol) and THF (0.5 mL). Flash column 
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chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 20% EtOAc in hexanes) afforded 
the title compound (3be) as a yellow oil (52 mg, 0.12 mmol, 46% yield). IR max/cm-1 (film): 2927, 2251, 
1980, 1722, 1595, 1497, 1328, 1165, 1127, 1075, 904, 725; 1H NMR (400 MHz, CDCl3) : 8.61 (1H, d, J 
= 5.5 Hz), 7.60-7.35 (8H, m), 7.21 (1H, dd, J = 5.5, 2.2 Hz), 7.16-7.08 (3H, m), 6.38 (2H, t, J = 2.1 Hz), 
5.75 (1H, s); 13C NMR (100 MHz, CDCl3) q, J = 32.2 Hz), 
129.2, 125.9 (q, J = 3.8 Hz), 124.0 (q, J = 3.7 Hz), 124.0 (q, J = 272.8 Hz), 118.3, 113.5, 112.4, 111.9, 58.7; 




Prepared according to general procedure D using potassium hydride (36.3% dispersion in mineral oil, 41 
mg, 0.38 mmol), 1H-imidazole (26 mg, 0.38 mmol), (4-(((2R,6S)-2,6-
dimethylmorpholino)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate (167 mg, 
0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 4% MeOH in DCM) afforded 
the title compound (3bi) as a white amorphous solid (52 mg, 0.16 mmol, 64% yield). IR max/cm-1 (film): 
3150, 3127, 2974, 2931, 2877, 2811, 2773, 2205, 1660, 1599, 1432, 1325, 1084, 1058, 931, 721, 651; 1H 
NMR (400 MHz, CDCl3) : 8.51 (1H, s), 8.19 (1H, dd, J = 8.4, 0.7 Hz), 8.04 (1H, dd, J = 8.4 Hz, 0.5 Hz), 
7.86 (1H, m), 7.77-7.71 (1H, m), 7.61 (1H, s), 7.57-7.51 (1H, m), 7.25 (1H, m), 3.94 (2H, s), 3.78-3.69 




; m/z LRMS (ESI + APCI) found [M+H]+ 323.2, C19H23N4O+  requires 323.2. 
2-Methyl-4-(4-((4-(phenylthio)pyridin-3-yl)methyl)piperazin-1-yl)quinoline (3bf) 
 
Prepared according to general procedure C sodium hydride (60% dispersion in mineral oil, 6 mg, 0.15 
mmol), benzenethiol (16 L, 0.15 mmol), (3-((4-(2-methylquinolin-4-yl)piperazin-1-yl)methyl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (73 mg, 0.10 mmol) and DME (0.4 mL). Flash column 
chromatography (silica gel, gradient elution: 100% EtOAc to 1% NEt3 in EtOAc) afforded the title 
compound (3bf) as an orange oil (15 mg, 0.034 mmol, 34% yield). IR max/cm-1 (film): 3061, 2933, 2825, 
2361, 2340, 2205, 1589, 1574, 1416, 1283, 1192, 1136, 1006, 905, 726; 1H NMR (400 MHz, CDCl3) : 
8.44 (1H, s), 8.22 (1H, d, J = 5.4 Hz), 7.98 (2H, t, J = 7.7 Hz), 7.65-7.58 (1H, m), 7.56-7.51 (2H, m), 7.48-
7.39 (4H, m), 6.75 (1H, s),  6.71 (1H, d, J = 5.4 Hz), 3.75 (2H, s), 3.33-3.17 (4H, m), 3.87-3.78 (4H, m), 
2.68 (3H, s); 13C NMR (100 MHz, CDCl3) 













Prepared according to general procedure C sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 
mmol), benzenethiol (77 L, 0.75 mmol), triphenyl(3'-(trifluoromethyl)-[2,2':5',3''-terpyridin]-4''-
yl)phosphonium trifluoromethanesulfonate (356 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 100% EtOAc) followed by a second flash column (20% EtOAc, 10% NEt3 in 
hexanes) afforded the title compound (3bd) as a yellow amorphous solid (132 mg, 0.32 mmol, 65% yield). 
IR max/cm-1 (film): 3060, 2925, 2227, 1569, 1448, 1429, 1331, 1285, 1162, 1138, 1019, 906, 727, 689; 1H 
NMR (400 MHz, CDCl3) : 8.98 (1H, d, J = 1.9 Hz), 8.76 (1H, d, J = 4.8 Hz), 8.40 (1H, s), 8.37 (1H, d, J 
= 5.5 Hz), 8.28 (1H, d, J = 2.0 Hz), 7.88 (1H, td, J = 7.8, 1.8 Hz), 7.80-7.76 (1H, m), 7.55-7.39 (6H, m), 
6.80 (1H, d, J = 5.4 Hz); 13C NMR (100 MHz, CDCl3) 
q, J = 5.0 Hz), 135.4, 132.0, 130.2, 130.0, 
129.8, 128.9, 125.0 (q, J = 33.0 Hz), 123.4 (q, J = 273.1 Hz), 123.8, 123.7, 120.7; 19F NMR (365 MHz, 









Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 µL, 0.38 mmol), 
N-methylaniline (40.6 L, 0.38 mmol), triphenyl(2-((pyridin-3-ylmethyl)thio)pyrimidin-4-
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yl)phosphonium trifluoromethanesulfonate (153 mg, 0.25 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel was packed with hexanes and neutralized with NEt3: 15% EtOAc in toluene) 
afforded the title compound (3bh) as a yellow oil (29 mg, 0.093 mmol, 37% yield). IR max/cm-1 (film): 
3035, 2927, 2224, 1710, 1600, 1568, 1498, 1348, 1200, 975, 904, 726, 647; 1H NMR (400 MHz, CDCl3) 
: 8.64 (1H, d, J = 1.8 Hz), 8.47 (1H, dd, J = 1.5, 4.9 Hz), 7.87 (1H, d, J = 6.1 Hz), 7.77-7.72 (1H, m), 7.48-
7.41 (2H, m), 7.35-7.30 (1H, m), 7.25-7.19 (3H, m), 5.99 (1H, d, J = 6.0 Hz), 4.36 (2H, s), 3.44 (3H, s); 
13C NMR (100 MHz, CDCl3) 
; 
m/z LRMS (ESI + APCI) found [M+H]+ 309.2, C17H17N4S+  requires 309.1. 
5-(((4-(4-Methoxyphenoxy)pyrimidin-2-yl)oxy)methyl)-3-phenylisoxazole (3bg) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.375 mmol), 4-methoxyphenol (47 mg, 0.38 mmol), 15-crown-5 (74 L, 0.38 mmol), triphenyl(2-((3-
phenylisoxazol-5-yl)methoxy)pyrimidin-4-yl)phosphonium trifluoromethanesulfonate (166 mg, 0.25 
mmol) and THF (0.5 mL). Flash column chromatography (silica gel, gradient elution: 4% EtOAc in toluene 
to 8% EtOAc in toluene) afforded the title compound (3bg) as a clear oil (52 mg, 0.14 mmol, 55% yield). 
IR max/cm-1 (film): 3053, 2917, 2848, 2247, 1610, 1574, 1504, 1441, 1272, 1244, 1193, 1080, 905, 726, 
693; 1H NMR (400 MHz, CDCl3) : 8.36 (1H, d, J = 5.6 Hz), 7.80-7.74 (2H, m), 7.47-7.42 (3H, m), 7.10-
7.04 (2H, m), 6.96-6.90 (2H, m), 6.53 (1H, d, J = 5.6 Hz), 6.51 (1H, s), 5.42 (2H, s), 3.82 (3H, s); 13C NMR 
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(100 MHz, CDCl3) 

; m/z LRMS (ESI + APCI) found [M+H]+ 376.2, C21H18N3O4+  requires 376.1. 
4-(4-Methoxyphenoxy)-2-((1-(4-phenoxyphenoxy)propan-2-yl)oxy)pyridine (3bp) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.375 mmol), 4-methoxyphenol (47 mg, 0.38 mmol), 15-crown-5 (74 L, 0.38 mmol), (2-((1-(4-
phenoxyphenoxy)propan-2-yl)oxy)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (183 
mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 10% EtOAc in hexanes) 
afforded the title compound (3bp) as a clear oil (56 mg, 0.13 mmol, 50% yield). IR max/cm-1 (film): 3042, 
2932, 2836, 2578, 2250, 2050, 1594, 1502, 1488, 1472, 1218, 1203, 1147, 906, 839, 728; 1H NMR (400 
MHz, CDCl3) : 7.99 (1H, d, J = 5.9 Hz), 7.34-7.27 (2H, m), 7.08-6.99 (3H, m), 6.99-6.88 (8H, m), 6.52 
(1H, dd, J = 5.9, 2.2 Hz), 6.12 (1H, d, J = 2.2 Hz), 5.56 (1H, m), 4.18-4.10 (1H, m), 4.08-4.01 (1H, m), 
3.82 (3H, m), 1.45 (3H, d, J = 6.4 Hz); 13C NMR (100 MHz, CDCl3) 









Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 6 mg, 0.15 
mmol), 4-methoxyphenol (19 mg, 0.15 mmol), 15-crown-5 (30 L, 0.15 mmol), ((6R,10S)-8-benzyl-
7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxalin-2-yl)triphenylphosphonium 
trifluoromethanesulfonate (71 mg, 0.10 mmol) and THF (0.2 mL). Flash column chromatography (silica 
gel: 30% EtOAc in hexanes) afforded the title compound (3bj) as a yellow oil (24 mg, 0.057 mmol, 57% 
yield). IR max/cm-1 (film): 3016, 2950, 1836, 2791, 2162, 2049, 1568, 1503, 1347, 1290, 1202, 907, 667; 
1H NMR (400 MHz, CDCl3) : 8.59 (1H, s), 7.73 (1H, s), 7.50 (1H, s), 7.24-7.19 (2H, m), 7.14-7.09 (3H, 
m), 7.00-6.94 (2H, m), 6.88-6.81 (2H, m), 3.85 (3H, s), 3.46 (2H, s), 3.33-3.21 (2H, m), 2.98-2.87 (2H, m), 
2.52 (2H, t, J = 8.3 Hz), 2.34-2.25 (1H, m), 1.81 (1H, d, J = 10.6 Hz); 13C NMR (100 MHz, CDCl3) 












Prepared according to general procedure C sodium hydride (60% dispersion in mineral oil, 12 mg, 0.30 
mmol), benzenethiol (31 L, 0.30 mmol), (8-chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-
dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate 
(159 mg, 0.20 mmol) and THF (0.40 mL). Flash column chromatography (silica gel was packed with 
hexanes and neutralized with NEt3, gradient elution: 60% CH2Cl2 in hexanes to 70% CH2Cl2 in hexanes to 
10 % MeOH in CH2Cl2 ) followed by a second flash column (silica gel was packed with hexanes and 
neutralized with NEt3, gradient elution: 9.5% CH2Cl2, 0.5% NEt3 in toluene to 8% CH2Cl2, 2% NEt3 in 
toluene) afforded the title compound (3bm) as a white solid (82 mg, 0.17 mmol, 83% yield). 198-201 °C;  
IR max/cm-1 (film): 3055, 2977, 2918, 2862, 2360, 2339, 2049, 1693, 1546, 1430, 1222, 1109, 748; 1H 
NMR (400 MHz, CDCl3) : 8.08 (1H, d, J = 5.4 Hz), 7.54-7.42 (5H, m),  7.21 (1H, d, J = 1.9 Hz), 7.18-
7.09 (2H, m), 6.44 (1H, d, J = 5.4 Hz), 4.14 (2H, q, J = 7.2 Hz), 3.90-3.70 (2H, br), 3.50-3.40 (1H, m), 
3.28-3.10 (3H, m), 3.04-2.83 (2H, m), 2.54-2.43 (1H, m), 2.40-2.27 (3H, m), 1.25 (3H, t, J = 7.1 Hz); 13C 




; m/z LRMS (ESI + APCI) found [M+H]+ 
491.2, C28H28ClN2O2S+  requires 491.2. 









Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), benzeneselenol (40 L, 0.38 mmol), (2-((4-chlorophenyl)((1-(ethoxycarbonyl)piperidin-4-
yl)oxy)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (196 mg, 0.25 mmol) and 
THF (0.5 mL). Flash column chromatography (silica gel: 30% EtOAc in toluene) afforded the title 
compound (3bn) as a clear oil (93 mg, 0.18 mmol, 70% yield). IR max/cm-1 (film): 3289, 3049, 2927, 2667, 
2349, 2245, 1690, 1567, 1226, 1085, 1014; 1H NMR (400 MHz, CDCl3) : 8.20 (1H, d, J = 5.2 Hz), 7.65-
7.60 (2H, m), 7.48-7.36 (3H, m), 7.32 (1H, d, J = 1.5 Hz),  7.30-7.23 (4H, m), 6.96 (1H, dd, J = 5.3, 1.7 
Hz), 5.47 (1H, s), 4.13 (2H, q, J = 7.2 Hz), 3.65-3.50 (3H, m), 3.25-3.14 (2H, m), 1.80-1.70 (1H, m), 1.70-
1.46 (3H, m), 1.26 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) 









Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.38 mmol), 1H-pyrrole (26 L, 0.38 mmol), (4-((R)-(benzyloxy)((1S,2R,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate (199 mg, 0.25 mmol) and THF 
(0.5 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt3: 
80% EtOAc in hexanes) followed by another flash column (silica gel, gradient elution: 100% EtOAc to 5% 
NEt3 in EtOAc) afforded the title compound (3bk) as white solid (61 mg, 0.14 mmol, 54% yield). mp: 70-
76 °C; IR max/cm-1 (film): 3149, 3064, 3030, 2932, 2862, 1635, 1599, 1479, 1357, 1256, 1066, 959, 731, 
695; 1H NMR (400 MHz, CDCl3) : 8.09-8.02 (2H, m), 7.75-7.63 (4H, m), 7.54-7.47 (1H, m), 7.41-7.30 
(5H, m), 6.40 (2H, t, J = 2.2 Hz), 5.80-5.66 (1H, m), 5.32 (1H, br), 4.99-4.85 (2H, m), 4.48 (2H, s), 3.48-
3.34 (1H, m), 3.20-3.05 (2H, m), 2.77-2.58 (2H, m), 2.32-2.22 (1H, m), 1.86-1.46 (5H, m); 13C NMR (100 
MHz, CDCl3) 
br), 
118.5, 114.3, 111.6, 108.8 (br), 71.6, 60.8, 57.1, 43.3, 40.0, 27.9, 27.8, 22.7 (br); m/z LRMS (ESI + APCI) 






2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate (3bo) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 11 mg, 
0.28 mmol), 3-methoxybenzenethiol (34 L, 0.28 mmol), (3-((3S,8R,9S,10R,13S,14S)-3-acetoxy-10,13-
dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (120 mg, 0.15 mmol) and THF (0.3 mL). Flash column 
chromatography (basic alumina, gradient elution: 20% EtOAc in hexanes to 30% EtOAc in hexanes) 
afforded the title compound (3bo) as a clear oil (49 mg, 0.092 mmol, 61% yield). IR max/cm-1 (film): 3246, 
3032, 2935, 2797, 2361, 2341, 2162, 1655, 1571, 1446, 1402, 1282, 1162, 1010, 814, 726; 1H NMR (400 
MHz, CDCl3) : 8.20 (1H, s), 8.14 (1H, d, J = 5.0 Hz), 7.35 (1H, t, J = 8.0 Hz), 7.11-7.07 (1H, m), 7.05-
7.02 (1H, m), 7.00-6.95 (1H, m), 6.65 (1H, d, J = 5.3 Hz), 5.97-5.93 (1H, m), 5.43 (1H, d, J = 4.9 Hz), 
4.68-4.57 (1H, m), 3.82 (3H, s), 2.42-2.31 (3H, m), 2.20-2.00 (6H, m), 1.92-1.81 (2H, m), 1.77-1.52 (7H, 
m), 1.15-1.00 (8H, m); 13C NMR (100 MHz, CDCl3) 

; m/z 







Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 
0.375 mmol), N-(4-hydroxyphenyl)acetamide (57 mg, 0.38 mmol), 15-crown-5 (74 L, 0.38 mmol), (5-
chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)triphenylphosphonium 
trifluoromethanesulfonate (192 mg, 0.25 mmol) and DME (0.5 mL). Flash column chromatography (silica 
gel, gradient elution: 3% MeOH in DCM to 5% MeOH in DCM) afforded the title compound (3bl) as a 
clear oil (49 mg, 0.12 mmol, 48% yield). IR max/cm-1 (film): 3317, 3062, 2929, 2252, 1980, 1676, 1599, 
1504, 1313, 1151, 904, 725; 1H NMR (400 MHz, CDCl3) : 8.76 (1H, d, J = 2.3 Hz), 8.66 (1H, s), 7.84-
7.79 (2H, m), 7.72 (1H, d, J = 2.3 Hz), 7.41-7.33 (4H, m), 7.20-7.14 (1H, br), 6.24-6.18 (3H, m), 3.09 (3H, 
s), 2.43 (3H, s), 2.17 (3H, s); 13C NMR (100 MHz, CDCl3) 











Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 6 mg, 0.15 
mmol), 3-methoxybenzenethiol (19 L, 0.15 mmol), (3-(2-((2-methyl-5-(4-((4-methylpiperazin-1-
yl)methyl)benzamido)phenyl)amino)pyrimidin-4-yl)pyridin-4-yl)triphenylphosphonium 
trifluoromethanesulfonate (90 mg, 0.10 mmol) and THF (0.2 mL). Flash column chromatography (silica 
gel was packed with hexanes and neutralized with NEt3: 4% MeOH in DCM) afforded the title compound 
(3bq) as a yellow solid (40 mg, 0.063 mmol, 57% yield,  6% regioisomer) mp: 78-84 °C; IR max/cm-1 
(film): 3246, 3032, 2935, 2797, 2361, 2341, 2162, 1655, 1571, 1446, 1402, 1282, 1162, 1010, 814, 726; 1H 
NMR (400 MHz, CDCl3) : 8.69 (1H, s), 8.56 (1H, d, J = 5.1 Hz), 8.35 (1H, d, J = 2.1 Hz), 8.29 (1H, d, J 
= 5.5 Hz), 7.86 (1H, s), 7.77 (2H, d, J = 8.2 Hz), 7.58 (1H, dd, J = 8.1, 1.6 Hz), 7.41 (2H, d, J = 8.2 Hz), 
7.31-7.19 (3H, m), 7.09 (1H, d, J = 5.1 Hz), 7.07-7.04 (1H, m), 7.02-7.00 (1H, m), 6.95 (1H, dd, J = 8.3, 
2.4 Hz), 6.78 (1H, d, J = 5.5 Hz), 3.75 (3H, s), 3.56 (2H, s), 2.60-2.41 (8H, br), 2.35 (3H, s), 2.30 (3H, s); 





; m/z LRMS (ESI + APCI) found [M+H]+ 632.4, C36H38N7O2S+  requires 632.3. 
Methyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-5-cyclopropylpicolinate (3bv) 
 
Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 11 mg, 
0.275 mmol), 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-hydroxyphenyl)urea (67.1 mg, 0.203 mmol), 
15-Crown-5 (40.3 L, 0.203 mmol), (5-cyclopropyl-2-(methoxycarbonyl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (79.3 mg, 0.14 mmol) and DME (0.27 mL). Flash 
column chromatography (silica: 70% EtOAc in hexanes) followed by a second flash column (silica, gradient 
elution: 85% EtOAc, 5% NEt3 in hexanes to 100% EtOAc) afforded the title compound (3bv) as an off-
white amorphous solid (28 mg, 0.055 mmol, 40% yield). IR max/cm-1 (film): 3350, 3310, 3125, 3082, 2957, 
1731, 1710, 1599, 1552, 1504, 1482, 1418, 1301, 1229, 1203, 1173, 1110, 984, 831, 733; 1H NMR (400 
MHz, CDCl3) : 9.24 (1H, s), 9.00 (1H, s), 8.28 (1H, s), 8.12 (1H, d, J = 2.2 Hz), 7.69-7.55 (4H, m), 7.20-
7.13 (3H, m), 3.78 (3H, s), 2.27-2.18 (1H, m), 1.12-1.05 (2H, m), 1.00-0.94 (2H, m); 13C NMR (100 MHz, 
(CD3)2SO)  164.8, 163.6, 152.5, 148.4, 147.7, 146.3, 139.3, 136.8, 132.0, 131.8, 126.7 (q, J = 30.2 Hz), 
123.1, 122.8 (q, J = 272.2 Hz), 122.3 (q, J = 1.8 Hz), 121.2, 120.6, 116.8 (q, J = 5.4 Hz), 110.0, 52.3, 8.3, 
8.0; 19F NMR (365 MHz, (CD3)2SO)  m/z LRMS (ESI + APCI) found [M+H]+ 506.1, 
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